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Abstract 
 
 
 
 
The rapid development of stem cell technology has raised hopes for new and 
even revolutionary treatments for cardiac and other disorders with tissue damage. 
The adult human heart has very limited capability to regenerate and undergo 
extensive repair which is needed, for example, after myocardial infarction. 
Pluripotent stem cells, human embryonic stem cells (hESC) and human induced 
pluripotent stem (iPS) cells can be differentiated into cardiomyocytes by multiple 
methods. In spite of this development, therapeutic use of stem cell-derived 
cardiomyocytes is in its infancy. 
However, functional cardiomyocytes can be differentiated from stem cells and 
they are themselves very useful as a cardiac cell model. Development of human iPS 
technology has raised the hope for the potential use of differentiated cardiomyocytes 
even further. By this method, patient specific stem cell lines can be derived and 
therefore disease models for genetic illnesses can be obtained. 
The present thesis describes the differentiation of cardiomyocytes from 
pluripotent stem cells. The differentiation potential of several hESC lines and iPS 
cells was evaluated and the differentiated cells were characterized. Furthermore, the 
differentiation potential of hESC and iPS cells cultured on mouse and human feeder 
cells was monitored. Differentiation was performed by two differentiation methods, 
spontaneously in embroid bodies (EBs) and in co-culture with mouse visceral-
endoderm-like cells (END-2 cells). In addition to the cardiac aspect, the formation 
of EBs and the differentiation of germ layers were evaluated in general. 
Differentiated cells were characterized by multiple molecular biology methods and 
their electrophysiological properties were also determined. 
Pluripotent stem cells can be differentiated into functional cardiomyocytes even 
though the differentiation efficiency is low and cell lines differ in their cardiac 
differentiation potential. The differentiated cells beat spontaneously and expressed 
specific cardiac markers. The populations of the differentiated cardiomyocytes were 
heterogenous, containing mainly ventricular cardiomyocytes with varying 
maturation states. However, some of the differentiated cells had relatively mature 
characteristics, resembling adult human cardiac phenotype.  
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Tiivistelmä 
 
 
 
 
Kantasolutekniikan odotetaan luovan uusia hoitomuotoja vaikeisiin, kudostuhosta 
johtuviin sairauksiin, kuten sydänsairauksiin. Aikuisen ihmisen sydämen 
uusiutumiskyky on hyvin rajallinen, eikä sydän pysty korjautumaan itsestään. Täten 
esimerkiksi sydäninfarktin jälkeen sydämeen jää vaurioituneelle alueelle sydämen 
toimintaa heikentävä arpi. Ihmisen alkion kantasolut ja ihmisen 
uudelleenohjelmoidut kantasolut (iPS- solut) ovat pluripotentteja kantasoluja, jotka 
pystyvät erilaistumaan periaatteessa kaikiksi kehon soluiksi. Näitä soluja voidaan 
monin eri menetelmin erilaista myös sydänlihassoluiksi, eli kardiomyosyyteiksi. 
Huolimatta siitä, että erilaistettuja sydänlihassoluja ei pystytä vielä kliinisesti 
hyödyntämään, ovat ne käyttökelpoisia käytettäväksi ihmisen sydänsolumallina. 
IPS-solujen käyttö mahdollistaa myös potilasspesifisten kantasolulinjojen ja täten 
myös potilasspesifisten sydänlihassolujen aikaansaamisen. Täten vaikeiden 
geneettisten sydänsairauksien mallintaminen solutasolla on mahdollista. 
Väitöskirjatutkimuksessani kuvataan sydänlihassolujen erilaistaminen sekä 
ihmisen alkion kantasoluista että ihmisen iPS-soluista. Tutkimuksessani verrattiin 
eri kantasolulinjojen erilaistumiskykyä sekä myös eri kantasoluviljelyssä 
käytettävien tukisolutyyppien vaikutusta erilaistumiseen. Sydänerilaistumisen 
lisäksi, embryoid bodien (EB) muodostumista tutkittiin myös yleisemmällä tasolla. 
Tämän lisäksi, erilaistetut sykkivät sydänlihassolut karakterisoitiin 
molekyylibiologisin ja elektrofysiologisin menetelmin. 
Tämän väitöskirjatutkimuksen tulokset osoittavat, että pluripotentit kantasolut 
erilaistuvat toiminnallisiksi sydänlihassoluiksi. Erilaistuneet solut sykkivät 
spontaanisti ja ilmentävät kardiomyosyyteille spesifisiä geenejä ja proteiineja. 
Erilaistumistehokkuus on kuitenkin matala ja erilaistumistehokkuus vaihtelee eri 
kantasolulinjojen välillä. Erilaistetut sydänlihassolut ovat pääosin kammioperäisiä 
sydänlihassoluja, mutta erilaistunut solupopulaatio sisältää myös eteisperäisiä ja 
johtoratajärjestelmän solutyyppejä. Tämän lisäksi, erilaistettujen solujen 
kypsyysaste vaihtelee. Kuitenkin osa soluista todettiin olevan aikuisen ihmisen 
sydänlihassolujen kaltaisia elektrofysiologisilta ominaisuuksiltaan.   
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1. Introduction 
The adult human heart has limited capability to regenerate and undergo extensive 
repair such as that needed, for example, after myocardial infarction. The rapid 
development of stem cell technology has raised hopes for new and even 
revolutionary treatments for cardiac and other disorders with tissue damage. 
Pluripotent stem cells, human embryonic stem cells (hESC) and induced pluripotent 
stem (iPS) cells, have the ability to differentiate into functional cardiomyocytes by 
multiple differentiation methods (Kehat et al., 2001, Mummery et al., 2003, Zhang 
et al., 2009, Freund et al., 2010). By contrast, the cardiac differentiation capability 
of adult, multipotent stem cells found in fetal and adult tissues is unresolved. The 
only adult stem cells that clearly have the capability to differentiate into beating 
cardiomyocytes are cardiac progenitor cells (Oh et al., 2003, Goumans et al., 2007).  
Even though cardiomyocytes can be differentiated, their therapeutic use is in its 
infancy. However, functional cardiomyocytes can be differentiated from stem cells 
and they are themselves very useful as a cardiac cellular model. In addition, the 
differentiating event is valuable for developmental studies. Even though hESC 
derived cardiomyocytes resemble fetal cardiomyocytes exhibiting immature 
functional and structural characteristics compared to adult cardiomyocytes, they 
possess many promising capabilities for the pharmaceutical industry and for basic 
academic research. The development of human iPS technology (Takahashi et al., 
2007, Yu et al., 2007) has raised the potential use of differentiated cardiomyocytes 
even more. By this method, patient specific stem cell lines can be derived and 
therefore disease models for severe illnesses can be obtained. 
However, cardiac differentiation is still uncontrolled and inefficient. Even though 
new better defined differentiation methods have been published, spontaneous 
differentiation in embryoid bodies and slightly more directed differentiation in co-
culture with END-2 cells are still widely used. In addition, hESC lines vary in their 
capabilities to differentiate towards cardiac linage. 
The objective of present thesis was to evaluate the differentiation of pluripotent 
stem cells (hESC and iPS cells) to cardiomyocytes and to characterize the 
differentiated cells. In addition, the differentiation potential of several hESC lines 
cultures on mouse and human feeder cells was evaluated. Differentiation was 
performed by two differentiation methods and in addition to multiple molecular 
biology characterisation methods, the electrophysiological properties of 
differentiated cardiomyocytes were determined. 
 18 
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2. Review of the literature 
 
2.1 Stem cells 
Stem cells are unspecialized cells capable of renewing themselves through cell 
division or they can be differentiated to become tissue- or organ-specific cells with 
special functions (Wobus and Boheler, 2005). Classification of stem cells is 
represented in Figure 1. The cells in the embryo until the 8-cell morula stage are 
totipotent; they can produce the whole organism. Stem cells derived from the inner 
cell mass (ICM) of the blastocyst are no longer totipotent but pluripotent, having 
the ability to differentiate basically into all cell types of the body. In addition, 
certain organs have multipotent stem cells which have even more limited 
differentiation ability (Wobus and Boheler, 2005). 
Stem cells enable diverse developmental studies e.g. early human lineage 
commitment, cell differentiation and maturation. They can serve as a unique human 
cell model for academic research as well as for the pharmaceutical industry. In 
addition, the progress in stem cell research has raised hopes for novel cell therapy 
treatments of severe diseases entailing tissue and cell damage like diabetes, 
neurological disorders, and cardiac failure. These hopes and developments are 
building on the successes of bone marrow hematopoietic stem cell (HSCs) 
transplants that have more than 30 years of patient applications in blood diseases 
and cancer (Thomas et al., 1959, Weissman, 2000). 
 
 20 
 
 
 
Figure 1. Origin and classification of stem cells. Zygote is totipotent, it can form any type of 
cells and the whole organism. Pluripotent human embryonic stem cells (hESC) are derived 
from the inner cell mass of the blastocyst-staged embryo. Induced pluripotent cells (iPS 
cells) are also pluripotent and are derived from human somatic cells by reprogramming with 
pluripotency inducing factors. Multipotent stem cells can be isolated from fetus or adult 
tissues. Figure is modified from pictures by Catherine Twomey 
(http://www.nationalacademies.org/stemcells).  
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2.1.1 Pluripotent stem cells 
2.1.1.1 Human embryonic stem cells 
The term “embryonic stem (ES) cell” was introduced in 1981 to distinguish 
embryo-derived pluripotent cells from teratocarcinoma-derived pluripotent 
embryonal carcinoma (EC) cells (Martin, 1981). First ES cells were derived from 
mouse ICM in the same year (Evans and Kaufman, 1981) and in 1994 Bongso and 
co-workers reported the successful isolation of human ICM cells and their continued 
culture for at least two passages in vitro (Bongso et al., 1994). The first permanent 
human embryonic stem cell (hESC) lines were derived more than a decade ago by 
Thomson and co-workers (Thomson et al., 1998) and these lines are still widely 
used. hESC have been derived from ICM of blastocyst (Thomson et al., 1998), 
morula (Strelchenko et al., 2004) or even from late stage (7-8 days) preimplantation 
embryos (Stojkovic et al., 2004). Human embryos have been donated for research 
by couples undergoing in vitro fertilisation treatments and they would have 
otherwise discarded because being excess or poor quality embryos. 
hESCs are capable of proliferating extensively at undifferentiated state in vitro 
and have the ability to differentiate towards all three germ layers and furthermore 
can, in principle, give rise to all cell types of the body. hESC express transcription 
factors and surface markers associated with undifferentiation, such as Octamer-4, 
POU domain , class 5, transcription factor 1 (Oct4), Nanog homeobox (Nanog), Sex 
determining region Y-box 2 (Sox2), Stage specific embryonic antigen 4 (SSEA-4), 
Tumor-related antigen 1-60 (TRA-1-60) and TRA-1-81(Hoffman and Carpenter, 
2005). Telomerase and alkaline phosphatase activity of hESCs is high and the 
karyotype should be normal and remain unaltered during extended culture periods 
(Hoffman and Carpenter, 2005). 
2.1.1.2 Induced pluripotent stem cells 
The cloning of the first mammal, “Dolly” the sheep, demonstrated that nuclei 
from a differentiated cell can be reprogrammed into undifferentiated state (Wilmut 
et al., 1997). The cloning of Dolly was achieved by a technique called somatic cell 
nuclear transfer (SCNT), where the oocyte nucleus is replaced by a nucleus derived 
from a somatic cell. In principle, embryonic stem cells can also be derived from 
embryos produced by SCNT enabling the production of patient specific hESC lines. 
However, this technique has major ethical reservations, since human embryos would 
be produced only for ES cell production and a large number of human oocytes 
would be needed. In addition, many countries have prohibited human cloning by 
law (Yamanaka, 2008). SCNT is represented in Figure 2. 
hESC contain factors that can induce reprogramming of somatic cell nucleus 
(Cowan et al., 2005, Allegrucci et al., 2007). Therefore somatic cell fusion with ES 
cell regenerates pluripotent cells. However, pluripotent cells obtained by fusion 
contain both chromosomes from the ES cell and from the somatic cell resulting in 
rejection if implanted (Yamanaka, 2008). Cell fusion is represented in Figure 2.  
Nevertheless, the above-mentioned findings led researchers to search for factors 
that induce reprogramming. Finally, in 2006 Takahashi and Yamanaka introduced 
four pluripotent genes; Oct4, Sox2, c-myc and Krupple-like family transcription 
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factor 4 (Klf4), that could reprogram mouse embryonic as well as adult fibroblasts 
into pluripotent stem cells (Takahashi and Yamanaka, 2006). The following year the 
same factors were used to make induced pluripotent cells (iPS cells) from human 
fibroblasts (Takahashi et al., 2007). Human iPS cells were also obtained by 
Thomson and co-workers by using Oct4 and Sox2 in combination with Nanog and 
Lin-28 homolog (Lin28) instead of c-myc and Klf4 (Yu et al., 2007). Ever since, the 
development in this field has been very intensive and this technique has been 
designated as a major breakthrough in stem cell research. The iPS cells are 
illustrated in Figure 1 and 2. 
 
 
Figure 2. Pluripotent hESC lines can, in principle, be derived from embryos obtained by 
somatic cell nuclear transfer (up), where the nucleus from the somatic cell is transferred to 
an enucleated egg. Pluripotent hESCs can also be obtained by fusing a somatic cell with an 
ES cell (right). The somatic cell can also be reprogrammed to plutipotent state by 
pluripotency inducing factors. Figure is modified from pictures by Catherine Twomey 
(http://www.nationalacademies.org/stemcells).  
 
The iPS cells have the same genome as the person whose cells have been 
reprogrammed and this makes it possible to obtain patient specific stem cells. These 
cells can be differentiated and they can serve as a cell or disease model or even may 
lead to stem cell therapies in the future (Dimos et al., 2008, Park et al., 2008). 
The iPS cells share the characteristics of hESCs, such as expression of 
pluripotency markers, differentiation capability and need for supporting matrix of 
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the feeder layer. In  addition, the cell culture and differentiation methods are similar 
for both stem cell types (Takahashi et al., 2007).  
2.1.2 Multipotent stem cells 
2.1.2.1 Fetal stem cells 
Fetal stem cells can be obtained either from fetus or from extra-embryonic 
structures like umbical cord blood, amniotic fluid, Wharton’s jelly, the amniotic 
membrane and the placenta (Hemberger et al., 2008, Pappa and Anagnou, 2009). 
The use of fetus itself as a source of stem cells has major ethical reservations 
whereas extra embryonic structures can be named as an ideal stem cell source. 
These tissues are dispensable after birth and have a large mass of tissue making the 
stem cells easy to harvest. In addition, stem cells of fetal origin express stem cell 
markers similar to hESCs, whereas their differentiation potential resides between the 
hESCs and adult stem cells (Guillot et al., 2007, Pappa and Anagnou, 2009). 
2.1.2.2 Adult stem cells 
Adult stem cells are undifferentiated cells found in differentiated tissues that have 
limited self-renewal and differentiation capacity, usually restricted to cell types of 
the tissue in which they originate (Choumerianou et al., 2008). Even though adult 
stem cells have limited differentiation and self-renewal capability, they are well 
suited for therapeutic purposes; patients’ own stem cells can be used and therefore 
rejection is circumvented. In addition, adult stem cells have no ethical reservations 
and are easy to isolate (Choumerianou et al., 2008). 
 As mentioned, probably the best known source of stem cells is bone marrow 
(BM). Autologous BM transplants have been used in many patients with cancers, 
including those of the hematolymphoid system (lymphomas and leukemias), of 
plasma cells (multiple myeloma), and breast cancer (Thomas et al., 1959, Thomas, 
1999, Weissman, 2000). BM contains two types of multipotent stem cells. 
Hematopoietic stem cells (HSC) give rise to all cell types of blood (Orkin, 2000) 
and mesenchymal stem cells (MSCs) can be differentiated into multiple 
mesenchymal tissue cell types such as bone, cartilage, adipose and muscle cells 
(Pittenger et al., 1999). In addition to BM, MSCs can be found in virtually all 
postnatal organs and tissues, e.g. from adipose tissue (da Silva Meirelles et al., 
2006). Adipose tissue-derived stem cells (ASC) are easy to harvest in large numbers 
and they are reported to have similar properties and differentiation potential as BM-
MSCs (Zuk et al., 2001, Zuk et al., 2002, Lindroos et al., 2009).  
2.1.2.3 Cardiac stem cells 
Classically, the heart has been classified as a post-mitotic organ. However, 
support for the endogenous regenerative ability of the heart has come from studies 
determining the age of human cells. The lifespan of human cardiomyocytes has been 
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successfully studied by utilizing 14C levels of cardiac cells and according to the 
results, over an average human lifespan, half on the cardiomyocytes are replaced 
(Bergmann et al., 2009). Further evidence for the regenerative ability of the heart 
has come from recent studies of human cardiac progenitor cells. Human cells with 
the ability to differentiate into cardiomyocytes have been obtained from myocardial 
biopsies (Goumans et al., 2007). Several types of cells with stem cell characteristics 
have been discovered from the heart including cells expressing stem cell factor 
receptor (c-Kit) (Bearzi et al., 2007) or stem cell antigen-1 (Sca-1) on their cell 
surface (Oh et al., 2003). In addition, cells expressing the homeodomain 
transcription factor islet-1 (Isl-1) (Laugwitz et al., 2005), side population cells (SP) 
(Pfister et al., 2005) and cells able to grow in cardiospheres have been found 
(Messina et al., 2004). Cardiac progenitor cells have been nominated as a candidate 
cells for cardiac regeneration and intensive work is ongoing to activate these cells to 
proliferate and differentiate in situ. However, the origin and specific capabilities 
forming functional cardiac cells of these progenitors need to be more thoroughly 
determined (Gonzales and Pedrazzini, 2009). 
2.2 Characteristics of human embryonic stem cells 
2.2.1 Stem cell lines  
At the end of the year 2009, the total number of hESC lines worldwide was 
estimated to be 1 071 (Loser et al., 2010). Even though the number of hESC lines 
has markedly increased since 2005, the estimation being 414 lines at that time, two 
lines H1 and H9 (WiCell Research Institute) have been the most used hESC lines in 
stem cell research (Guhr et al., 2006, Scott et al., 2009, Loser et al., 2010).  In spite 
of the large number of lines, the number of available and well-characterized lines is 
probably considerably lower. Due to the poor characterization data published, it 
remains an open question whether the cell lines reported in the scientific literature 
manifest the characteristics of human pluripotent cell lines and are available for 
research (Loser et al., 2010). 
The wide use of WiCell lines is partly due to polices and legislation on the use of 
hESC in certain countries, such as in the USA. On August 2001, President Bush 
introduced a law which proscribed the federal funding for research made with hESC 
lines derived after that date (Murugan, 2009). Even though President Obama 
revoked Bush’s policy in 2009 enabling the use of hESC lines derived after 2001, 
federal funding for the derivation of new hESC lines is still prohibited (Murugan, 
2009). Nevertheless, due to the differences between stem cell lines, the dominance 
of few lines in hESC research may reduce the universal applicability of the results 
and therefore even limit the development of the field (Loser et al., 2010). 
If hESCs are to be used in clinical applications, there should be enough stem cell 
lines to cover the spectrum of transplant antigens and further to avoid immune 
rejection problems. It has been estimated that in the UK, 150 randomly obtained 
hESC lines would provide a worthwhile human leukocyte antigen (HLA) match for 
most potential recipients (Taylor et al., 2005). In addition, genetic variation of hESC 
lines would also be preferable for drug screening and safety pharmacology 
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applications of the pharmaceutical industry (Ingelman-Sundberg and Rodriguez-
Antona, 2005, Allegrucci and Young, 2007).  
Derivation and culture techniques of hESCs vary between laboratories 
(Allegrucci and Young, 2007). In addition, the blastocyst stage, the stage when 
hESCs are derived, is characterized by high levels of epigenetic activity, including 
DNA methylation, X chromosome inactivation, and dynamic chromatin remodelling 
(Bibikova et al., 2006). Therefore it is understandable that hESC lines differ in 
terms of epigenetics, for example H7 hES cells do not express the marker for X-
chromosome inactivation as do H9 and hES 25 (Hoffman and Carpenter, 2005). In 
addition, it is not known how stable the epigenetic profile of ES cells is during long-
term culture, nor how it may change as the cells differentiate along different 
developmental pathways (Bibikova et al., 2006). 
Therefore variations in derivation and maintenance combined with the genetic 
variation of the human samples leads to hESC lines with different properties 
(Allegrucci et al., 2005, Allegrucci and Young, 2007). However, in spite of the 
known possibilities of genetic or environmental influences on the phenotype of the 
hESC lines, many of the lines have been published without detailed characterization 
data (Adewumi et al., 2007). In addition, probably due to the laborious and costly 
maintenance of several hESC lines, only few studies have been published 
comparing the characteristics of several hESC lines. According to these comparison 
studies, hESCs have been shown to be similar in regard to expression of 
pluripotency markers but after cells start to differentiate, the expression of 
differentiation markers and further differentiation propensity varies between 
different hESC lines (Adewumi et al., 2007, Kim et al., 2007, Osafune et al., 2008). 
Due to this observation it has been suggested, that the most suitable hESC line 
should be chosen according to its propensity to differentiate towards the linage of 
interest (Osafune et al., 2008).  
In addition to changes due to derivation and culture techniques, prolonged 
culturing and passaging of hESC may alter them for adaptive changes such as 
karyotypic changes, increased growth rate or reduced apoptosis (Draper et al., 
2004a, Draper et al., 2004b, Enver et al., 2005, Hanson and Caisander, 2005, Baker 
et al., 2007, Hovatta et al., 2010, Narva et al., 2010). According to karyotype studies 
based on G-banding, during prolonged culture the most frequent karyotype changes 
observed are gains of chromosomes 12, 17 and X, which are also seen in germ cell 
tumors (Baker et al., 2007). In addition, more similarities between hESC and tumor 
cells have been found in studies using higher resolution DNA analysis (Hovatta et 
al., 2010, Narva et al., 2010).   
2.2.2 Cell culture 
hESCs need specialized culture conditions to maintain their pluripotency and 
stable karyotype and phenotype. In addition to specialized culture media, feeder 
cells are needed for attachment, nourishment and to keep hESCs undifferentiated. 
Originally hESC were derived and cultured on top of mouse embryonic fibroblast 
(MEF) feeder cells in a culture media consisting fetal calf serum (FBS) (Thomson et 
al., 1998, Reubinoff et al., 2000). Later on, human based feeders have been used to 
replace MEFs (Hovatta et al., 2003, Inzunza et al., 2005, Skottman and Hovatta, 
2006) and KnockOut Serum Replacement (SR) (Invitrogen, Carlsbad, CA, USA) 
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has replaced FBS in hESC culture medium. FBS is a problematic reagent because it 
contains unknown components and different serum batches vary in their capability 
to maintain pluripotency or even differentiate hESCs. Although SR still consists of 
many animal based components, it is more defined and also beneficial effects on 
hESCs’ proliferation (Koivisto et al., 2004).      
Much effort has been invested in replacing living feeder-cells by some other 
substrates to develop feeder-free hESC culture systems (Akopian et al., Xu et al., 
2001, Thomas et al., 2009). Commercially available Matrigel (BD Biosciences), 
laminin and fibronectin have been reported to maintain pluripotent state of hESCs 
(Amit et al., 2000, Amit et al., 2004, Rosler et al., 2004). 
 Passaging of hESC is another challenging step in hESC production. Stem cells 
grow in colonies (Figure 3) and these colonies have to be broken either 
mechanically or enzymatically during passaging. Mechanical cutting of the colonies 
into smaller pieces does not expose the cells to xenogenic enzymes (e.g. trypsin or 
collagenase IV) which dissociate them in a more uniform way but at the same time 
disrupt their cell surface adhesion molecules and communication with other cells. In 
addition, dissociation of hESC to single cell stage may predispose cells to 
karyotypic changes (Brimble et al., 2004). Either way, passaging is a laborious and 
also critical step in the production of hESCs.  
A more defined culture system is needed to fulfil the needs of clinical 
applications and also for hESC research. To avoid xenogenic materials and 
problems caused by lot-to-lot variation of FBS, growth factors and enzymes used in 
passaging would enhance the hESC production and make it more standardized and 
consistent. 
 
 
 
Figure 3. hESC line H7 colony cultured on human foreskin fibroblast feeders. Scalebar 
200µm. 
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2.3 Development and differentiation markers of the 
heart 
In vertebrates, the heart is the first organ to form and its circulatory function is 
essential for the viability of the embryo (Buckingham et al., 2005). Myocardial cells 
are derived from mesoderm, a germ layer which emerges during gastrulation from 
the primitive streak. The initial form of the heart is the heart tube which then 
undergoes multi-phased looping and finally forms the four-chambered heart 
(Buckingham et al., 2005).  
Studies of early stages of heart differentiation are hampered by the lack of early 
stage cardiac cell markers (Lough and Sugi, 2000). Transient expression of  
Brachyury T is widely used to depict mesoderm and furthermore cardiac lineage 
formation (Kispert and Herrmann, 1994).  According to present knowledge, there 
are two cardiac progenitor cell populations, called the heart fields, that contribute to 
the formation of the heart (Buckingham et al., 2005). One lineage contributes to the 
formation of the left ventricle, partly the right ventricle, the atrioventricular canal 
and atria. The other lineage is responsible for the formation of the outflow tract as 
well as the all right ventricle and atria. The latter field, called the secondary or 
anterior heart field is marked by Islet-1 (Isl-1), the LIM homeodomain transcription 
factor. This field forms two thirds of the embryonic heart, including the cardiac 
muscle, smooth muscle and endothelial cells (Cai et al., 2003). Other early markers 
for cardiac progenitors are mesoderm posterior 1 and 2 (MESP1 and MESP2), 
which are transiently expressed in newly formed mesoderm at the primitive streak 
(Kitajima et al., 2000).  In mammals, bone morphogenic proteins (BMPs), 
transforming growth factor β superfamily (TGF-βs) and the fibroblast growth 
factors (FGFs) have been found to be essential for heart development and these 
factors regulate the activation of myocardial regulatory genes such as NK2 
transcription factor related  gene, locus 5 (Nkx 2.5) and GATA binding protein-4 
(GATA4) (Brand, 2003). The developmental steps in heart formation are illustrated 
in Figure 4. 
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Figure  4. A simple schematic of developmental steps in heart formation. Embryonic stem 
cells have the potential to differentiate into cell types of all three germ layers, endoderm, 
mesoderm or ectoderm. Mesoderm is the origin of cardiac cells and it has been shown that 
cardiac differentiation inducing signals are to a large extent of endoderm origin. Two cardiac 
progenitor cell populations, the heart fields, contribute to the formation of the heart. The left 
ventricle is formed only from the primary heart field, whereas the atria and the right ventricle 
are formed from both of the progenitor cell populations. 
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2.4 Production of cardiomyocytes  
2.4.1 Cardiac differentiation potential of stem cells 
Pluripotent stem cells, hESC and iPS cells have the ability to differentiate into 
functional cardiomyocytes by multiple methods (Kehat et al., 2001, Mummery et 
al., 2003, Zhang et al., 2009, Freund et al., 2010). By contrast, the cardiac 
differentiation capability of adult, multipotent, stem cells is controversial. The only 
adult stem cells that clearly have the capability to differentiate into beating 
cardiomyocytes are cardiac progenitor cells (Oh et al., 2003, Goumans et al., 2007).  
Adult human bone marrow mesenchymal stem cells have been shown to 
differentiate in vitro into cardiomyocyte-like cells with expression of cardiac 
specific genes (Rangappa et al., 2003, Antonitsis et al., 2007, Antonitsis et al., 
2008). However, differentiation was induced by 5-azacytidine, a cytosine analog 
that can reduce DNA methyltransferase activity in the cells (Tsuji-Takayama et al., 
2004) or in co-culture with cardiomyocytes (Wang et al., 2006). Similar methods 
have been reported to produce cells with cardiomyocyte phenotype from human 
adipose-derived stem cells and spontaneously beating cells were moreover obtained 
after co-culture with neonatal rat cardiomyocytes (Choi et al., 2010). When bone 
marrow–derived hematopoietic cells were transplanted directly into the hearts of 
mice subjected to acute myocardial infarction, no transdifferentiated bone marrow–
derived cardiomyocytes were found in the damaged myocardium. However, cell 
fusion has been found to occur at very low levels, where bone marrow–derived cells 
have fused with host cardiomyocytes outside the infarction area (Nygren et al., 
2004). 
Many clinical studies have evaluated the therapeutic potential of human bone 
marrow derived stem cells (e.g. mesenchymal stromal cells or mononuclear cells) to 
improve cardiac function after myocardial infarction (Gonzales and Pedrazzini, 
2009, Mathiasen et al., 2009, Wei et al., 2009, Miettinen et al., 2010). No evidence 
of cardiac regeneration characterised by differentiation of implanted stem cells into 
cardiomyocytes and other cardiac cell lineages has been reported. Some studies, but 
not all, report beneficial effects on heart function and on symptoms (Wollert et al., 
2004, Janssens et al., 2006, Lunde et al., 2006, Schachinger et al., 2006). These 
benefits have been suggested to be short-term and according to five-year follow-up 
treatment with BMC was not able to achieve sustained improvements on heart 
function (Meyer et al., 2009). Nonetheless, the congruent results of these studies 
show that therapeutic use of human bone marrow stem cells is apparently safe.  
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Figure 5. Cardiac differentiation cascade and the differentiation methods. From the top; 
Markers for different stages of cardiac differentiation, steps in cardiac differentiation and the 
differentiation methods. END-2 differentiation has two variables, hESC are either plated on 
top of END-2 cell layer or hESC are cultured as EBs in suspension in END-2 conditioned 
medium. In EB method, differentiation can be performed spontaneously or with 
differentiation inducing growth factors. Monolayer differentiation is initiated with feeder 
free hESC cultures. Culturing of hESC and differentiation with activin A and bone 
morphogenic protein-4 (BMP-4) is preformed on top of Matrigel. By this method, beating 
monolayer can be obtained whereas END-2 and EB method produce thee dimensional 
beating areas.  
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2.4.2 Differentiation methods 
2.4.2.1 Spontaneous differentiation in embryoid bodies 
hESC and iPS cells can be differentiated spontaneously as embryoid bodies (EB) 
(Figure 5). In principle, during EB formation the culture condition for stem cells is 
changed from two-dimension into three-dimensional structure. First pluripotent stem 
cells are either enzymatically or mechanically dissociated to small cell clusters. 
Secondly cells are allowed to form aggregates in suspension and after a few days the 
formed EBs are normally plated down on matrix coated cell culture plates 
(Kurosawa, 2007). After hESCs have been removed from the environment which 
supports the undifferentiated state, they start to differentiate towards three germ 
layers in the cell aggregates (Itskovitz-Eldor et al., 2000). During the early stages of 
suspension culture, the cell aggregate transforms into a cystic body and a trilayer 
shell composed of extra cellular proteins forms around EB (Sachlos and Auguste, 
2008). The paracrine and endocrine signalling determine the fate of the stem cell. 
Similarly as in embryo this signalling may lead to the formation of concentration 
gradient in the EBs and further influence the cell differentiation (Sachlos and 
Auguste, 2008). 
EB formation has characteristics similar to those of embryonal development 
(Keller, 1995) and therefore the interplay of different germ layers and their 
influences on cell differentiation can be studied in EB cultures. EB differentiation, 
such as cardiac differentiation, is particularly well documented with mouse ES cells 
(Hescheler et al., 1997, Boheler et al., 2002). However, the EB formation and 
spontaneous differentiation from hESC has proven to be more difficult and 
inefficient if compared to mouse counterpart (Wobus et al., 1991, Kehat et al., 
2001). When mouse ES cells are differentiated in EBs, beating areas appear 1 day 
after plating, and, within 2–10 days, 80–90% of EBs reveal beating areas (Wobus et 
al., 1991). In the hESC differentiation beating areas are observed later and the 
differentiation efficiency is  much lower, usually under 10% (Kehat et al., 2001). 
Cardiomyocytes can be obtained from hESC and iPS cells by spontaneous 
differentiation in EBs (Itskovitz-Eldor et al., 2000, Kehat et al., 2001, Zhang et al., 
2009). EB differentiation is also widely used in the production of other cell types 
such as neuronal cells, hematopoietic cells, adipocytes and chondrocytes (Pera and 
Trounson, 2004). For the whole existence of hESC, EB differentiation has been a 
widely used differentiation method due to its relatively simple and inexpensive 
nature. 
There are multiple methods for EB formation (Kurosawa, 2007). Suspension 
culture in bacterial-grade cell culture dishes was first developed for mouse ES cells 
(Doetschman et al., 1985) and was later used in cardiomyocyte differentiation from 
hESCs (Itskovitz-Eldor et al., 2000, Kehat et al., 2001). In this method 
enzymatically dissociated cells aggregate when cultured unattached in the culture 
medium. hESCs are vulnerable to dissociation to the single cell stage (Thomson et 
al., 1998, Amit et al., 2000, Kehat et al., 2001, Xu et al., 2002) and therefore hESCs 
have been dissociated into small aggregates of cells to retain the cell-to-cell contact 
(Amit et al., 2000, Pyle et al., 2006). To scale up EB formation in suspension 
cultures, bioreactors and spinner flasks have also been used (Messina et al., 2004, 
Kurosawa, 2007, Yirme et al., 2008). 
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Cardiomyocytes have also been differentiated by the hanging drop method, 
where single cell suspension is pipetted in small drops onto a petri dish cover and 
the cover is then inverted on top of a dish (Takahashi et al., 2003, Burridge et al., 
2007). The drop hangs because of the surface tension and provides a good 
environment for the cells to aggregate and form the EB. The hanging drop-method 
is not suitable for long term EB differentiation because medium change is 
impossible (Kurosawa, 2007). Overall hanging drop method is very laborious and 
therefore not suitable for large scale experiments.  
Recent studies indicate that EB size has an effect on cardiomyocyte 
differentiation as well as on differentiation in general (Burridge et al., 2007, 
Bauwens et al., 2008, Mohr et al., 2010). Therefore the number of cells should be 
measurable in order to optimize differentiation. The hanging drop method makes it 
possible to standardize the initial amount of hESC. However, Ng and co-workers 
developed a more robust method than hanging drops, a forced aggregation (FA) 
system for hematopoietic differentiation and this has also been used in 
cardiomyocyte differentiation (Ng et al., 2005, Burridge et al., 2007). FA mimics 
the hanging drop method; the cells are forced to aggregate by centrifugation in 
round bottomed, low-adherence 96-well plate wells. The medium change is possible 
to the wells and therefore longer culture times can be used and differentiation 
inducing agents can also be added to the culture medium (Burridge et al., 2007). 
Two-dimensional cell pieces can also be produced by microprinting technique, 
where standard-size colonies are formed and then scraped into suspension culture 
(Bauwens et al., 2008, Niebruegge et al., 2009). EB differentiation techniques are 
summarized in Table 1. 
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Table 1. Summary of the EB differentiation techniques. 
 
EB differentiation techniques 
Method 
description 
Hanging 
drop 
Forced 
aggregation 
(FA) 
Suspension 
culture 
Microprinting 
technique Manual 
hESC colony 
dissociation Enzymatic dissociation 
Detachment of 
microprinted 
colonies 
Manual  
cutting 
EB formation 
Single 
cells/small 
aggregates 
form EB in a 
hanging drop 
Cell 
suspension is 
aggregated to 
EB by 
centrifuging in 
a 96-well plate 
Spontaneous 
aggregation in 
suspension 
One cell colony or cell 
colony piece forms an EB in 
suspension 
Formed EBs transferred for 
suspension culture Suspension culture continues 
EB culture 
After suspension culture EBs are plated on a coated cell culture plate 
Advantages 
Gentle EB 
formation in 
a drop 
because of 
gravity 
Scalable, 
straightforward, 
cell number per 
EB easy to 
standardize 
Straightforward 
Cell number 
per EB easy to 
standardize 
Gentle, 
non-
enzymatic 
hESC 
colony 
dissociation 
Disadvantages Laborious, non-scalable 
hESC colonies 
have to be 
dissociated to 
single cell stage 
Forming EBs 
randomly sized 
Need for 
microprinting 
technique for 
colony 
formation 
Laborious, 
non-
scalable 
Reference (Takahashi et al., 2003) (Ng et al., 2005) 
(Doetschman et al., 
1985) 
(Bauwens et al., 
2008, Niebruegge 
et al., 2009) 
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2.4.2.2 Differentiation in mouse visceral-endoderm-like cell co-cultures 
A more controlled way to differentiate cardiomyocytes from hESCs is in co-
culture with mouse endodermal-like cells (END-2) (Figure 5), particularly in the 
absence of serum and with ascorbic acid (Mummery et al., 2003, Passier et al., 
2005). The differentiation inducing factors are secreted from END-2 cells and 
therefore the END-2 conditioned medium can also be used in cardiomyocyte 
differentiation (Graichen et al., 2008). END-2 cells support the differentiation 
towards endodermal and mesodermal derivatives (Mummery et al., 2003, Passier et 
al., 2005, Beqqali et al., 2006) and according to embryonal development studies, 
anterior visceral endoderm is essential in normal heart development (Lough and 
Sugi, 2000). It has therefore been suggested that cardiomyocyte differentiation 
could be mediated by END-2 cells directly or by hESC derived endodermal cells 
(Passier et al., 2005).   
However, the mechanism or the specific factors inducing cardiac differentiation 
by END-2 cells are not clearly known. Systematic testing of END-2 conditioned 
medium revealed that END-2 cells were able to clear insulin from the medium (Xu 
et al., 2008a). Insulin has been shown to inhibit cardiac differentiation by 
suppressing endoderm and mesoderm formation and favouring ectoderm 
differentiation (Freund et al., 2008). Insulin acts via the insulin-like growth factor-1 
receptor (IGF-1R) and phosphatidylinositol 3-kinase (PI3K/Akt) pathway and has 
been suggested to inhibit epithelial to mesenchymal transition by elevated levels of 
E-cadherin (Freund et al., 2008). In addition, IGF/PI3K/Akt has been shown to have 
a role in the proliferation of immature cardiomyocytes (McDevitt et al., 2005) which 
suggests that this pathway has a dual role in cardiomyogenesis. 
END-2 cells were not the only type of cells which depleted insulin from the 
culture media. Similar phenomenon was observed with MES1-cells (Mummery et 
al., 1986) and mouse embryonic fibroblasts (MEFs) which do not have the cardiac 
inducing effect (Xu et al., 2008a). Therefore insulin depletion is likely not the 
cardiac inducing factor of END-2 cells. On the contrary, prostaglandin I2 (PGI2) was 
found to be secreted by END-2 cells at elevated levels if compared to other types of 
mouse cells lacking cardiac inductive effect. Including PGI2 in differentiation 
medium without END-2 conditioning resulting a similar level of cardiac 
differentiation as END-2 conditioned medium (Xu et al., 2008a).  
In addition to the PGI2, inhibition of p38 mitogen activated protein kinase 
(MAPK) increases the cardiac differentiation rate (Graichen et al., 2008). Selective 
MAPK inhibitors (molecules SB203580 and SB202190) (Cuenda et al., 1995) were 
found to increase the differentiation rate when added to END-2 conditioned 
medium. However, the inductive effect of these molecules was concentration 
dependent, at high concentrations (>15 μM) cardiomyocyte formation was 
decreased and finally inhibited (Xu et al., 2008a). The use of p38 inhibitor 
PD169316 also causes mouse ES cells to differentiate towards neural linage 
meanwhile the cardiac mesoderm formation is inhibited (Aouadi et al., 2006). 
Therefore the inhibition of MAPK has a partially opposite effect on mouse and 
human cells.  
Even though some factors of END-2 cells that affect cardiac differentiation have 
been identified (Graichen et al., 2008, Xu et al., 2008a), the role of END-2 cells as a 
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whole in cardiac differentiation remains a mystery. The END-2 differentiation 
techniques are compared in Table 2. 
 
Table 2. Summary of the END-2 differentiation techniques. 
END-2 differentiation techniques 
Method description END-2 co-culture END-2 conditioned medium 
END-2 culturing Culturing on END-2 cells, mitomycin-C- treatment and preparation of END-2 cell layers on cell culture plates or flasks 
Preparation of the 
differentiation media 
Normal cell culture 
medium 
Production of conditioned 
medium (culture medium on 
END-2 cell layer for 4-5 days) 
hESC colony dissociation Manual cutting Enzymatic dissociation 
Plating hESC colony pieces 
onto END-2 cell layer EB formation in suspension 
 EBs to be cultured in the conditioned medium 
Differentiation procedure 
Culturing with medium change after every 3-5 days 
Beating areas observed ~7 days after initiation of co-culture 
~12 days after exposure to 
conditioned medium 
Advantages Simple, fast, no enzymatic dissociation 
Conditioned medium can be 
stored, no plating of EBs 
necessary, scalable 
Disadvantages 
END-2 cell layer 
production needed right before 
differentiation 
Preparation of conditioned 
medium (possible lot-to-lot 
variation) 
Reference (Mummery et al., 2003, Passier et al., 2005) (Xu et al., 2008a) 
 
2.4.2.3 Differentiation with defined growth factors 
Cardiac differentiation consists of complex signalling network and currently 
there is no single factor to direct stem cells to differentiate effectively towards 
cardiac lineage. Laflamme and co-workers used a combination of activin A and 
BMP-4 in cardiomyocyte differentiation (Laflamme et al., 2007) (Figure 5). This 
cascade of factors enhances mesoendoderm formation, an early precursor cell 
lineage which gives rise to mesoderm and endoderm. Mesoderm is the origin of 
cardiac cells and it has been shown that cardiac differentiation inducing signals are 
to a large extent of endoderm origin (Lough and Sugi, 2000). Therefore 
mesoendoderm induction would yield more efficient human embryonic stem cell-
derived cardiomyocyte (hESC-CM) differentiation.  
A stepwise differentiation protocol was also developed by Yang and co-workers 
(Yang et al., 2008). This protocol involves the induction of primitive streak-like 
population, in addition to the formation of cardiac mesoderm and expansion of 
 36 
cardiac lineages. The protocol is based on EB differentiation and comprises three 
stages. Growth factors BMP-4, FGF, activin A, vascular endothelial growth factor 
(VEGF) and dickkoptf homolog 1 (DKK1) were used in varying combinations. 
Mesoendoderm formation has also been induced by Wnt3A, an activator of the 
canonical Wnt/β-catenin signalling pathway (Tran et al., 2009).  
Taken together, even though the use of growth factors may enhance cardiac 
differentiation, pure populations of cardiomyocytes can not currently be produced 
and enrichment methods are still needed. Due to multi-phased differentiation 
protocols and the high costs of growth factors, the simple and functional EB 
differentiation method is still a widely used method in cardiomyocyte production. 
However, as in hESC culturing, more defined differentiation system should be 
developed for cardiomyocyte differentiation to enhance reproducibility and purity of 
the differentiated cardiomyocyte population. 
2.4.3 Enrichment of differentiated cardiomyocytes 
Due to the inefficient differentiation, the resulting cell populations are a mixture 
of different cell types and the yield of hESC-CM cultures is very low. EB 
differentiation in serum containing medium yields < 1%  and the more defined 
activinA/BMP-4 protocol yielded > 30% of cardiomyocytes (Laflamme et al., 
2007). Therefore differentiation methods need considerable upscaling and effective 
enrichment and purification methods should be developed before hESC-CM can 
undergo testing in large animal models and clinical use in the future. 
For certain research purposes, it is usually adequate to enrich the hESC-CM by 
mechanically dissecting beating areas from the differentiation cultures (Kehat et al., 
2001, Mummery et al., 2003). However, only 5-20% of the cells in the beating areas 
are positive for cardiac α-actinin (Passier et al., 2005).  
PercollTM gradient separation based on density gradient separation has been used 
in combination with the generation and maintenance of cardiac bodies (Xu et al., 
2006). After separation and 7 days of suspension maintenance, 50 % of the cultured 
EBs contained beating areas. However, this method has been difficult for others to 
reproduce (van Laake et al., 2006).  
Transgenic selection is one technique to enrich cardiomyocytes from hESC 
differentiation cultures. This method utilizes transgenic hESC lines where a gene of 
green fluorescent protein (GFP) or an antibiotic resistance gene is located under the 
control of a cardiac specific promoter (e.g. myosin light chain promoter) (Kolossov 
et al., 2005, Anderson et al., 2007, Huber et al., 2007, Xu et al., 2008b, Kita-Matsuo 
et al., 2009). Although this method is efficient, genetic modification is neither 
feasible for hESC or human iPS cell lines nor suitable for possible future clinical 
use (Mummery, 2010, Vidarsson et al., 2010).    
A recent study sorted cardiomyocytes from mixed cell populations by utilizing 
the endogenously expressed surface marker activated leukocyte cell-adhesion 
molecule, CD166 (ALCAM) (Rust et al., 2009). However, there is a lack of cardiac 
specific surface proteins and therefore a lack of antibodies to make sorting possible 
(Mummery, 2010). Nevertheless, fluorescence-activated cell sorting (FACS) was 
successfully used in selection by utilizing the high mitochondria content of 
cardiomyocytes (Hattori et al., 2010).  
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2.5 Characterization of differentiated cardiomyocytes 
2.5.1 Functional and structural analysis 
hESC-CM have the capacity to beat spontaneously (Kehat et al., 2001, Mummery 
et al., 2003). Beating cells are at an early stage relatively small and round and 
situated in circular accumulations in the EBs. At later stages, EBs gradually develop 
to be larger and the cells turn to be more elongated in shape and tend to accumulate 
in strands. Electron microscopy studies reveal that cardiomyocytes contain 
myofibrils which are first randomly and in a varying manner distributed throughout 
the cytoplasm. However, organized sarcomeric structures occur at later stages of 
differentiation with A, I, and Z bands. Close to the sarcomeres, mitochondia are also 
present. In addition, cells have intercalacted disks with gap junctions and 
desmosomes  (Kehat et al., 2001, Snir et al., 2003).   
2.5.2 Expression of cardiac markers 
The gene expression profiles of the hESC during cardiac differentiation (Beqqali 
et al., 2006, Synnergren et al., 2008a) and the differentiated hESC-CM have been 
studied by DNA microarray (Cao et al., 2008, Synnergren et al., 2008b, Kita-
Matsuo et al., 2009, Xu et al., 2009). These studies reveal that the molecular 
signature of hESC-CM resembles the cardiomyocytes from the human heart 
(Vidarsson et al., 2010).   
hESC-CM differentiation can be predicted by the transient expression of the early 
mesodermal marker Brachyury T. Brachyury T expression peak is detected at the 
time point of 3 days in END-2 co-cultures (Beqqali et al., 2006) and a day later in 
EBs (Bettiol et al., 2007). Brachyury T belongs to the family of transcription factors 
which are encoded by the T-box genes (Showell et al., 2004). This protein family 
functions in many developmental processes and has a sequence similarity with the 
DNA-binding domain, the T-domain (Showell et al., 2004). The phenotype of 
heterozygous Brachyury T mutant mice was first described by Nadine 
Dobrovolskaïa-Zavadskaïa in 1927, in these mice the axial development was not 
completed and they had a truncated tail (Dobrovolskaia-Zavadskaïa, 1927). 
Homozygous mice, however, display many mesodermal abnormalities and die 
shortly after gastrulation (Gluecksohn-Schoenheimer, 1938, Gluecksohn-
Schoenheimer, 1944). Brachyury T can be nominated as a classic transcription 
factor, it is localized in the nucleus and is an endogenous activator of mesodermal 
genes (Conlon et al., 1994, Kispert et al., 1995, Showell et al., 2004). In the embryo, 
Brachyury T expression is suggested to be induced by TGFβ and FGF signalling 
(Hemmati-Brivanlou and Melton, 1992, Amaya et al., 1993). Overall, very few 
direct targets for T-box genes have been identified. However, embryonic FGF 
(eFGF) (Casey et al., 1998), Brachyury-induced homeobox Bix4 (Tada et al., 1998) 
and XWnt11 (Tada and Smith, 2000) have been suggested as downstream targets for 
Brachyury T. 
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 Differentiation cascade can be further followed by the expression of cardiac 
regulatory transcription factors such as Islet-1 (Isl-1), Mesp 1, GATA-4, Nkx2.5 and 
T-box transcription factor 6 (Tbx6) (Graichen et al., 2008, Yang et al., 2008).  
Cardiac troponin T (cTnT) is encoded by the TNNT2 gene (Thierfelder et al., 
1994), is the tropomyosin-binding subunit of the troponin complex and can 
therefore be used for characterizing hESC-CM. Troponin complex is located on the 
thin filament of striated muscles and regulates muscle contraction in response to 
alterations in intracellular calcium ion concentrations as reviewed (Farah and 
Reinach, 1995, Tobacman, 1996). In addition to cTnT, other cardiac specific 
structural proteins are used for confirming cardiac phenotype of the beating hESC-
CM such as cardiac troponin I, myosins or cardiac α-actinin (Kehat et al., 2001, 
Mummery et al., 2003).  
In addition proteins of contractile apparatus, proteins of gap junctions and ion 
channels can be used in characterization of hESC-CM. Gap junctions are formed 
from connexin proteins and have an important role in signal transduction. Connexin 
43 (Cx43) is the most common form in the ventricle, Cx40 predominates in the atria 
and Cx45 is found in both atria and ventricle and also from Purkinje fibres (Gaborit 
et al., 2007). 
2.5.3 Electrophysiology 
hESC as well as iPS cell-derived cardiomyocytes exhibit heterogenic action 
potential (AP) morphologies which can be divided into nodal, atrial and ventricular 
subtypes according to the shape of AP  as represented in Figure 6 (He et al., 2003a, 
Zhang et al., 2009). If compared to the human neonatal or adult atrial or ventricular 
cardiomyocytes, hESC-CM have relatively positive maximum diastolic potential 
(MDP) and slow maximum rate of rise of the AP (dV/dtmax) and are therefore called 
embryonal atrial- and ventricular like cells (He et al., 2003a).  
Differentiated beating cells exhibit spontaneous APs and contractile activity and 
therefore express cardiac structural proteins and ionic currents (Kehat et al., 2001, 
He et al., 2003b, Mummery et al., 2003). During differentiation the expression of 
some ion channel genes increases suggesting that hESC-CM reach a more mature 
state with time in culture (Sartiani et al., 2007).   
Traditionally a patch clamp has been used in analyzing the action potential and 
also the electrophysiological properties of cardiomyocytes. Micro-electrode array 
(MEA) technology provides another useful platform to study cell electrophysiology, 
especially ES-derived cardiomyocytes (Hescheler et al., 2004, Reppel et al., 2004). 
In MEA, cells are plated on top of electrodes in a cell culture well-type platform and 
can be cultured and measured repeatedly for long periods of time. In addition, MEA 
can be utilized for testing the effects of pharmaceutical agents on hESC-CM (Braam 
et al., 2010). 
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Figure 6. Action potential phases and cardiomyocyte subtype specification A. Action 
potential (AP) parameters: Action potential amplitude (APA), maximum rate of rise of the 
action potential (dV/dtmax), action potential delay (ADP) and membrane diastolic potential 
(MDP). AP phase 0 is a rapid depolarization phase when the sodium channels are activated 
and membrane permeability is increased to Na+. Rapid depolarisation is followed by rapid 
repolarization phase 1 and plateau phase 2, where Ca2+ ions are entered to the cell 
throught L-type calcium channels. At phase 3, calcium channels are inactivated and 
repolarization is caused by outward potassium currents. Repolarization is due to the 
currents carried mainly by the slow Iks and rapid Ikr components of the delayed rectifier 
potassium channels. The Ikr current is produced by hERG channel (encoded by the human 
ether-à-go-go-related gene). By contrast, inward potassium current contributes to the 
maintenance of the resting membrane potential, phase 4. B-D. Classification of ventricular 
(B), atrial (C) an pacemaker-like (D) action potentials. Ventricular action potential has a 
prominent plateau phase whereas atrial action potential is more triangularly shaped. 
Pacemaker-like cells are characterized by slower upstroke velocity and amplitude if 
compared to ventricular and atrial type of cells.  
2.5.4 Excitation-contraction coupling 
The calcium handling properties of hESC-CM have not been studied intensively. 
However, due to the few existing reports, hESC-CM possesses functional, albeit 
immature, calcium handling components when compared to adult cardiomyocytes 
(Dolnikov et al., 2006, Liu et al., 2007, Satin et al., 2008). For clinical applications, 
the calcium system should be functioning properly to hESC-CM to integrate 
properly after transplantation. Poor integration to the host myocardium could pose a 
threat of serious arrhythmias. In any case, a better understanding of calcium 
properties of the differentiated hESC-CM is needed.  
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2.6 Applications for human embryonic stem cell or 
induced pluripotent stem cell derived 
cardiomyocytes 
2.6.1 Human cardiac cell/tissue model 
Since the establishment of the first permanent hESC line (Thomson et al., 1998) 
there has been a great hope of replacing damaged heart tissue by hESC derived 
cardiomyocytes. However, many major problems need to be solved before hESC-
CM are usable in clinics. Before clinical use becomes a reality, it is likely that the 
hESC-CM will be applicable for drug discovery and safety pharmacology 
applications (Braam et al., 2009). Nevertheless, cardiac differentiation and the 
beating cells are already a useful tool for developmental biology and to study the 
pathophysiology of human cardiac diseases. In addition, iPS technology enables the 
production of patient specific cell lines which extends the potential use even further.  
2.6.1.1 Pathophysiology of cardiac diseases 
Many cardiac diseases are caused by gene mutations or gene-enviroment 
interactions. So far, these severe diseases have been studied in animal models, 
especially with transgenic mice. Even though mouse models can yield valuable 
information, differences between human and mouse physiology limit the 
applicability of the results, for example the much faster beating rate of the mouse 
may override the effects of arrhythmias which would be severe for humans (Freund 
and Mummery, 2009). 
Cardiomyocytes derived from genetically modified hESC could be used as a 
disease model. To construct a mutated hESC line and the disease model, the hESC 
line needs to be genetically manipulated. However, genetic manipulation of hESCs 
has proven to be more challenging if compared to mouse ES cells and only a limited 
number of reports of successful gene targeting and manipulation have been 
published (Braam et al., 2008, Giudice and Trounson, 2008).  
To obtain disease specific lines, the genetic manipulation step can be 
circumvented by deriving the iPS cell lines from patients with genetic diseases (Park 
et al., 2008, Ebert et al., 2009, Freund et al., 2010). The differentiation of these 
model iPS cells to the desired cell type makes it possible to study the development 
and the pathophysiology of the disease. In addition, the factors affecting the 
development and the progress of the disease can be studied (Freund et al., 2010).  
However, iPS cell technology is still in its infancy and it remains to be seen if 
differentiated cells really manifest the disease phenotype of the mutation they carry 
and serve as a real disease model (Freund and Mummery, 2009).   
2.6.1.2 Safety pharmacology and drug discovery 
The heart has been proven to be very sensitive to the side effects of 
pharmaceutical compounds. Severe reactions, such as syncope, arrhythmia and 
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sudden death, related polymorphic ventricular tachycardia, torsade de pointes (TdP), 
have led to the refusal of approval or the withdrawal from the market of many 
pharmaceutical agents (Roden, 2004). In the absence of a complete understanding 
and direct analysis of TdP, the regulatory authorities have adopted the QT 
prolongation as a marker for the possible development of drug-induced TdP even 
though it is not a perfect marker for arrhythmogenesis (Finlayson et al., 2004). 
Prolongation of the QT interval resulting from a delay in ventricular repolarization, 
whether drug-induced or, for instance, congenital arising from mutation of genes (to 
date LQT1-12), may be associated with TdP (Roden, 2004, Zareba and 
Cygankiewicz, 2008), although the relationship is complex (Shah and Hondeghem, 
2005). However, the QT interval is the cornerstone of the guidelines for the 
assessment of new chemical compounds in regard to proarrhythmic potential (ICH, 
2005b, ICH, 2005a). Delayed rectifier potassium current (IKr) is responsible for the 
repolarization of the action potential and the channel protein is encoded by the 
human ether-to-go-go-related gene (hERG) (Vandenberg et al., 2001, Pollard et al., 
2008). Inhibition of this hERG channel (KV11.1) and the subsequent inhibition of 
the IKr, is the predominant basis of drug-induced QT prolongation and TdP (Redfern 
et al., 2003, Hancox et al., 2008). Currently a number of preclinical models and 
assays have been employed by pharmaceutical companies (Carlsson, 2006, Pollard 
et al., 2008). These assays include in vivo QT assays, such as ECG telemetry of 
conscious dogs (Miyazaki et al., 2005), and in vitro assays, such as repolarization 
assay, which detects changes in the action potential delay (APD) of cardiac tissues 
(isolated animal Purkinje fibres, papillary muscles or cardiac myocytes) or the 
hERG channel assay where hERG current expressed in heterologous cell system 
(such as CHO- or HEK293-cells) or  native IKr is characterized (Finlayson et al., 
2004, Martin et al., 2004).  
Current methods are not fully adequate (Redfern et al., 2003, Lu et al., 2008). In 
addition, they are costly and the in vivo assays are ethically questionable because of 
the large number of animals used. Therefore there is a need for an in vitro method 
based on human cardiac cells that would bring additional value and reliability for 
testing novel pharmaceutical agents. 
Cardiomyocytes derived both from hESC and iPS cells have many potential 
applications in the pharmaceutical industry including target validation, screening 
and safety pharmacology. These cells would serve as an inexhaustible and 
reproducible human model system and preliminary reports of the validation of 
hESC-CM system already exist (Braam et al., 2010). However, much optimization 
and development remains to be done, especially because of the immature phenotype 
of these cells and problems due to the differentiation efficiency, heterogeneous 
hESC-CM populations and enrichment methods (Braam et al., 2009). 
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2.6.2 Regenerative medicine 
In principle, it would be possible to restore the function of the damaged heart by 
transplanting differentiated hESC or iPS cells. However, this may be one of the 
most challenging tasks to put into practice. The needed number of transplantable 
cells is high and they should be immunocompatible. In addition, the transplanted 
graft should integrate into the host myocardium and receive blood flow to remain 
vital, couple with host myocardium and contract in synchrony in response to the 
conduction system (Braam et al., 2009). 
Using iPS cells as a cell source, immunomatched cells can be produced but 
current methods for reprogramming entail infecting the somatic cells with multiple 
viral vectors (Takahashi et al., 2007, Yu et al., 2007), which precludes consideration 
of their use in transplantation medicine at this time. 
hESC-CM have been transplanted into healthy myocardium of rodents. The cells 
were reported to survive, form myocardial tissue and proliferate but they were 
usually separated from the rodent myocardium by a layer of fibrotic tissue 
(Laflamme et al., 2005, van Laake et al., 2007). When transplanted into infracted rat 
or mouse hearts, some beneficial effects for the function of the heart occurred 
(Laflamme et al., 2007, van Laake et al., 2007). However, after longer follow-up the 
positive effects were no longer present (van Laake et al., 2007, van Laake et al., 
2008, van Laake et al., 2009). It is questionable whether these temporary benefits 
are due to the formed myocardium or paracrine effects, as has been proposed for 
adult stem cells.   
Even though some information concerning transplantation can be obtained by 
using rodent models, studies with larger animals (pigs, goats and sheep) are 
warranted to give more accurate results regarding safety issues, electrical coupling 
and cardiac function. Usage of the iPS cells or ESC from the same species would 
eliminate the xeno barriers (Braam et al., 2009). 
In addition to the above-mentioned issues, the timing of cell therapy and the 
delivery methods still needs to be determined. It is likely that cells need supportive 
material during transplantation and therefore biomaterial research is also needed 
before clinical studies can be properly designed (Passier et al., 2008). 
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3. Aims of the study 
The objective of present thesis was to evaluate the differentiation of hESC and iPS 
cells to cardiomyocytes and to characterize the differentiated cells. In addition, the 
differentiation potential of several hESC lines was evaluated with two 
differentiation methods and the electrophysiological properties of the differentiated 
cardiomyocytes were determined. The specific aims of this study were the 
following: 
 
I. To evaluate the cardiac differentiation capabilities of several hESC lines 
with two differentiation methods.  
II. To study the spontaneous differentiation of different hESC lines into three 
germ layers 
III. To study the effect of different human and mouse feeder cells used in 
hESC and iPS cell culture on cardiac differentiation 
IV. To characterize the electrophysiological properties and maturation state of 
the differentiated cardiomyocytes  
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4. Materials and methods 
4.1 Cell culture 
4.1.1 Origin of cell lines and ethical approval 
HS lines (HS181, HS237, HS293, HS346, HS360, HS362, HS368 and HS401) 
derived at the Fertility Unit of Karolinska University Hospital, Huddinge 
(Karolinska Institutet, Stockholm, Sweden) (Hovatta et al., 2003, Inzunza et al., 
2005) were used in Studies I, II and IV. The derivation team had an approval from 
the Ethics Committee of the Karolinska Institutet for the derivation, characterization 
and differentiation of hESC lines. Regea Institute of Regenerative Medicine, 
University of Tampere, Finland has the approval of the Ethical Committee of 
Pirkanmaa Hospital District to culture hESC lines derived at the Karolinska Institute 
(Skottman R05051). 
The Regea 06/015 and 06/040 cell lines (Rajala et al., 2010) used in Studies I and 
IV and Regea 08/017 cell line (Skottman, 2010) used in Study III were derived at 
Regea. The National Authority for Medicolegal Affairs has given the permission for 
Regea to perform research with human embryos (Dnro 1426/32/300/05). In 
addition, Regea has approval from Ethical Committee of Pirkanmaa Hospital 
District to derive, culture, characterize and differentiate new hESC lines (Skottman 
R05116). The embryos used in hESC line derivation were surplus embryos donated 
by couples undergoing in vitro fertilization treatments. Both partners have signed an 
informed consent form after receiving oral and written descriptions of the research. 
The donors did not receive any financial compensation.  
H7 line used in Study III was purchased from WiCell Research Institute 
(Madison, WI, USA). The iPS cell line h106 used in Study III was derived at Regea 
from human foreskin fibroblasts (hFF) (American Type Culture Collection, 
Manassas, VA, USA). The Ethical Committee of Pirkanmaa Hospital District has 
granted approval for iPS cell research at Regea (Aalto-Setälä R0708).  
4.1.2 Human embryonic stem cell culture (I-IV) 
The hESC were cultured on a feeder cell layer of irradiated human fibroblasts 
(American Type Culture Collection, Manassas, VA, USA) in a medium (hES 
medium) consisting of Knockout Dulbecco’s modified Eagle medium (KO-DMEM) 
(Invitrogen, Carlsbad, CA, USA), 20% Serum Replacement (SR) (Invitrogen), 2 
mM GlutaMax (Invitrogen), 1% non-essential amino acids (Cambrex Bio Science 
Inc., Walkersville, MD, USA), 50 U/ml penicillin/streptomycin (Cambrex Bio 
Science Inc), 0.1 mM 2-mercaptoethanol (Invitrogen), and 8 ng/ml basic fibroblast 
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growth factor (bFGF) (R&D Systems, Minneapolis, MN, USA). Colonies were 
passaged mechanically on a weekly basis. 
In Study III, the Regea 08/017 and H7 lines were also cultured in similar culture 
medium as mentioned above on mitomycin C (Sigma-Aldrich, St. Louis, MO, USA) 
treated mouse embryonic fibroblast (MEF) feeder cell layers (Millipore Billerica, 
MA, USA) and passaged enzymatically by collagenase IV (Invitrogen) on a weekly 
basis.  
4.1.3 Human induced pluripotent cell culture (III) 
h1/06 cell line has been derived from human foreskin fibroblasts (hFF) (American 
Type Culture Collection) using lentivirus infection followed by retrovirus infection 
of Oct4, Sox-2, Klf4 and c-Myc (Takahashi et al., 2007). In Study III, h1/06 cells 
were cultured both on hFF and MEF feeders similarly as described above.  
4.2 Cardiomyocyte differentiation 
4.2.1 Spontaneous differentiation in embryoid bodies (I, IV) 
EB formation was performed by mechanically cutting the undifferentiated hESC 
colonies into small pieces and placing them on a U-shaped low attachment 96-well 
plate (Nunc, Roskilde, Denmark), one piece per well, in EB-medium (200 µl per 
well) consisting of KO-DMEM (Gibco Invitrogen, USA) supplemented with 20 % 
foetal bovine serum (FBS) (Gibco Invitrogen, USA), 1 % non-essential amino acids 
(Cambrex BioSciences, Verviers, Belgium), 1% L-glutamine (Invitrogen, USA), 
and 50 U/ml penicillin/streptomycin (Cambrex BioSciences, Verviers, Belgium). 
The hESC colonies were cut and detached in the same way as with normal 
passaging of hESCs, only the pieces were cut bigger, one cell colony split into 2-4 
pieces. EBs cells were cultured on the 96-well plate for seven days and the EBs 
formed were plated onto 0.1 % gelatine type A coated (Sigma-Aldrich, Germany) 
cell culture plates in EB medium. The EBs were allowed to attach to the bottom of 
the well and the medium was changed three times a week. The cell cultures were 
checked daily for beating areas under a phase contrast microscope (Olympus, 
Tokyo, Japan).  
4.2.2 Co-culture with mouse visceral-endoderm-like cells (II-IV) 
Cardiomyocyte differentiation was carried out by co-culturing hESC with mouse 
visceral-endoderm-like (END-2) cells, which were kindly donated by Prof. 
Mummery, Humbrecht Institute, Utrecht, Netherlands. END-2 cells were cultured in 
END-2 medium consisting 1:1 Dulbecco’s modified Eagle medium and Ham’s F12  
medium DMEM-F12 (Invitrogen) with 7.5 % fetal calf serum (FBS) (Mummery et 
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al., 1991). To initiate cardiomyocyte differentiation, undifferentiated hESC colonies 
were dissected mechanically into aggregates containing a few hundred cells and 
placed on the top of mitomycin C (Sigma-Aldrich) treated END-2 cells in hESC 
culture medium (described above) with 3 mg/ml ascorbic acid and without serum, 
serum replacement or bFGF (Passier et al., 2005). Differentiating cell colonies were 
monitored by microscopy daily (Olympus, Tokyo, Japan) and the medium was 
changed after 5, 8 and 12 days of culturing. After 16 days the 10% SR was added to 
the medium.  
4.2.3 Estimation of cardiac differentiation efficiency (I-III) 
In Studies I and II, the differentiation efficiency was calculated as a percentage of 
beating areas per total number of hESC colony pieces plated on END-2 cells or per 
total number of EBs.  
In Study III, undifferentiated cell colonies were dissociated by scraping from the 
hFF feeders or from the cell culture plate after MEF feeder removal. The number of 
cell pieces plated on END-2 cells was 30. However, the plated material also 
included smaller colony pieces and single cells which could not be quantified. 
Therefore the total number of plated cell colony pieces could not be quantified as 
precisely as when cell colonies were cut into pieces and the same efficiency 
determining method could not be used. Instead, from all the six variable cell lines, 
similar numbers of colonies were plated onto END-2 cell plates and the 
differentiation efficiency was determined by the average number of beating areas 
per 12-well plate well. In addition, to support the differentiation efficiency data, the 
percentage of troponin T positive cells versus the total cell number (4',6-diamidino-
2-phenylindole (DAPI) staining of nuclei) was determined after 21 days of END-2 
differentiation. The cells from three wells of a 12-well plate were trypsinized (20 
min. at +37ºC), resuspended in 5 ml of EB-medium with 15 % FBS. To standardize 
the analysis, the same wells were selected for dissociation from each cell line. The 
total number of cells was determined and 500 000 cells resuspended in a total 
volume of 12 ml with PBS were spun at 800 rpm for 5 minutes onto polysine slides 
(Thermo Scientific) by cytospin system (Cyto-Tech, Sakura). The cells were fixed 
and stained with anti-troponin T. 
4.3 Morphology and size analysis of embryoid bodies 
(I) 
The growth and morphology of the EBs was examined daily under a phase 
contrast microscope (Olympus, Tokyo, Japan). Pictures were taken from 10 EBs and 
the sizes were determined from the pictures during the suspension phase (seven days 
from the start of the differentiation protocol). The diameter of the EBs was 
measured manually, if the EBs were not round in shape, the average diameter was 
measured. To support this measurement, the cross-sectional area of each EB in the 
picture was determined using Cell^D imaging software (Olympus Soft Imaging 
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Solutions GmbH, Japan). The overall EB size for each cell line and each day was 
determined from the mean value of ten EBs.  
4.4 Gene expression studies 
4.4.1 RNA isolation and cDNA synthesis (I-III) 
Total-RNA was isolated in Studies I, II with the RNAeasy mini plus kit including a 
DNAse treatment (Qiagen, Valencia, CA, USA) and in study III with NucleoSpin® 
RNA II kit including a DNAse treatment (Machery-Nagel, Duren, Germany). The 
concentration and quality of RNA was monitored spectroscopically (Nanodrop, 
Wilmington, DE, USA) and 0.2-1 µg of total RNA was transcribed to 
complementary DNA either by Sensiscript reverse transcriptase (Qiagen) for reverse 
transcriptase polymerase chain reaction (RT-PCR) or for quantitative PCR (qPCR) 
purposes by High Capacity cDNA Reverse Transcription Kit (Applied Biosystems)  
according to the manufacturer’s instructions. 
4.4.2 Reverse transcriptase-polymerase chain reaction (II) 
The expression of β-actin (control), α- myosin heavy chain, atrial myosin light 
chain, ventricular myosin light chain, troponin T type 2, GATA-4, and connexin-45, 
Sox1, Brachyury T, BMP-4, AFP and KDR was determined by RT-PCR. 
Commercial heart RNA (Ambion, Austin, TX, USA) was used as a positive control.  
PCR reaction was performed using Phusion DNA-Polymerase (Finnzymes, Espoo, 
Finland) with 0.2 μM of primers and 1 µl of cDNA as a template. The amplification 
program included the initial denaturation step at 98◦C for 30 seconds followed by 32 
cycles of 10 seconds at 98◦C, 30 seconds at 63◦C and 30 seconds at 72◦C. The PCR 
end products were separated in agarose gel containing ethidium bromide and 
visualized under UV light. 
4.4.3 Quantitative polymerase chain reaction (I-III) 
The gene expression levels of the pluripotency, germ layer and differentiation 
markers in differentiating hESC in END-2 co-cultures (Studies II and III) and 
during EB differentiation (Study I) were assessed by quantitative polymerase chain 
reaction (qPCR). qPCR was performed according to standard protocols on an Abi 
Prism 7300 instrument (Applied Biosystems, Foster City, CA, USA) by either 
Taqman or SYBR-green chemistry. Cτ values were determined for every reaction 
and the relative quantification was calculated with the 2-ΔΔ Cτ method (Livak and 
Schmittgen, 2001). The data were normalized to the expression of the housekeeping 
gene Peptidyl-prolyl isomerase G (PPIG), Ribosomal protein large P0 (RPLP0) or 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and one sample was 
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nominated as the calibrator. At least two biological replicates from each timepoint 
and line were analyzed as triplicates or duplicates. Results are shown as the average 
values of biological replicates.  
4.5 Protein expression studies 
4.5.1 Tissue multi-array (I) 
In the Study I, the protein expression in the tissue sections from the 
differentiating EBs was assessed. The expression of pluripotency marker Oct4, 
different germ layer markers (mesodermal Brachyury T, endodermal AFP and 
ectodermal Sox1 and Paired box gene 6 (Pax6)) and the cardiac lineage marker 
Nkx2.5 were analyzed. In addition, caspase-3 was used to assess the number of 
apoptotic cells. EBs at the age of 2, 4, 6, 8, 10 and 12 days were collected (n=8) and 
fixed with 4 % paraformaldehyde for 2 hours. In addition, older EBs with and 
without beating areas were prepared for immunocytochemisty in a similar way. The 
samples were cryoprotected with 20% sucrose in PBS for several days. A tissue 
multiarray was prepared by punching 1mm holes in an inert medium as originally 
developed by Pelto-Huikko (Parvinen et al., 1992). The EBs were individually 
transferred to the wells filled with OCT compound. The multiarray was frozen on 
dry ice and 6µm frozen sections were cut throughout the chuck and thaw mounted 
on Polysine glass slides (Menzel, Braunschweig, Germany). Sections were stored at 
-70ºC until used. 
Immunocytochemistry was performed using the N-Histofine® Simple Stain MAX 
PO staining method (Nichirei Biosciences Inc., Tokyo, Japan). Antibodies used 
were mouse anti-Oct4 1:200, goat anti-Sox1 1:500, goat anti-AFP 1:500 (Santa Cruz 
Biotech) and rabbit anti-Brachyury T  1:300 (Abcam), Nkx2.5 1:200 (R&D 
Systems), caspase-3 1:500 (Cell Signalling Tech., Danvers, MA, USA) anti-Pax6 
1:300 (Developmental Studies Hybridoma Bank, The University of Iowa, Iowa City, 
IA, USA) and anti-cardiac Troponin T 1:50 (Abcam).  
The sections were incubated overnight at 4°C with primary antibodies followed 
by appropriate N-Histofine staining reagent for 30 min. ImmPACTTM (Vector 
Laboratories, Burlingame, CA, USA) diaminobenzidine-solution was used as the 
chromogen. All antibodies were diluted in PBS containing 1% BSA and 0.3% of 
Triton X-100. The sections were briefly counterstained with hematoxylin, 
dehydrated and embedded in Entellan. Controls included omitting the primary 
antibodies or replacing them with non-immune sera. No staining was seen in the 
controls. 
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4.5.2 Immunocytochemistry (I-IV) 
For the immunocytochemical stainings, the beating areas from the cell colonies 
(from END-2 or EB differentiations) were first cut with a scalpel and then dissected 
by collagenase II treatment (Mummery et al., 2003). Dissociated cells were plated 
on 0.1% gelatin coated 12- or 24-well tissue culture plates in a medium containing 
7.5 % (FBS). Beating areas were dissociated from co-cultures 14-25 days after 
plating and fixed 4-7 days after dissociation with 4 % paraformaldehyde (PFA) in 
phosphate buffered saline (PBS) for 20 min at room temperature (RT). Fixed cells 
were washed 2 x 5 min by PBS and permeabilized and blocked with 0.1% Triton X-
100, 1 % bovine serum albumin (BSA) and 10 % normal donkey serum in PBS for 
45 min at RT. The primary antibodies used (listed in the Table 3) were diluted to 
0.1% Triton X-100, 1 % bovine serum albumin (BSA) and 1 % normal donkey 
serum in PBS. The cells were incubated with primary antibodies overnight (12-16 
hours) at +4ºC. The primary antibody solution was removed and the cells were 
washed with 1% BSA in PBS.   
Secondary antibodies used were either Rhodamine Red (Jackson Immuno Research 
Laboratories Inc., West Grove, PA) or Alexa Fluor-488 or -568 (Invitrogen) 
conjugated anti-mouse, anti-rabbit or anti-goat antibodies. Secondary antibodies 
were diluted into 1% BSA in PBS 1:400 or 1:800 and incubated for 1 hour at RT. 
Omitting the primary antibody and using only secondary antibodies in the 
immunocytochemical protocol resulted in the disappearance of all positive staining. 
After secondary antibody incubation, the cells were washed in PBS 3-5 x 5 min and 
mounted in Vectashied mounting medium with DAPI. The immunostained cells 
were analyzed and documented by Olympus IX51 phase contrast microscope with 
fluorescence optics and with Olympus DP30BW camera. 
4.5.3 Western blot (I) 
EBs were collected at the age of 0, 3, 7, 10 and 20 days for protein isolation. 
Proteins were isolated by M-PER reagent (Pierce, Rockford, IL, USA) and the 
protein concentration was determined by BCA method (Pierce). Proteins were 
separated by 12% SDS-PAGE gel and transferred to PVDF-membrane (Hybond-P, 
GE-Healthcare, www.ge.com). Membrane was blocked with 2 % BSA (Sigma-
Aldrich) overnight at +4 ºC. Primary antibodies used were anti-Oct4 1:100 (Santa 
Cruz Biotech.), anti-Brachyury T 1:400 (Abcam), anti-AFP 1:200 (Santa Cruz 
Biotech), anti-Sox1 1:400 (Abcam) and they were diluted to TBS-Tween. Beta-actin 
1:1000 (Santa Cruz) was used as an endogenous control. Primary antibodies were 
incubated overnight at +4 ºC. Peroxidase-conjugated antibodies (1:4000) (Zymed, 
Invitrogen) were used for one hour at room temperature and ECLplus-kit (GE 
Healthcare) was used as the detection reagent. Exposure was done by CCD camera 
with Quantity One software (Biorad, Hercules, CA, USA).  
 
 51
4.6 Electron microscopy and immunoelectron 
microscopy (II) 
For electron microscopy, the dissociated beating cells were fixed with 2.5% 
glutaraldehyde overnight and subsequently postfixed with 1% osmium tetroxoide 
for one hour.  Cells were dehydrated and embedded in Epon. Ultrathin sections were 
counterstained with 1% uranyl acetate (30 minutes) and with lead citratate (5 
minutes). For immunoelectron microscopy 22-day-old cells were fixed with a 
mixture of 4% paraformaldehyde and 0.2% glutaraldehyde in PBS (0.2M) for 15 
minutes. Immunocytochemistry was performed using the ABC-method (Vectastain 
ABC Elite Kit, Vector Laboratories). The cells were incubated overnight with a 
mouse monoclonal antibody to Troponin-I (Chemicon) (diluted 1:100 in PBS 
containing 1% BSA and 0.1% Saponin) followed by incubation with a biotinylated 
sheep anti-mouse antibody (GE Healthcare, Bio-Sciences AB, Uppsala, Sweden) 
and the ABC-complex for 60 minutes each. Diaminobenzidine was used as a 
chromogen to visualize the sites expressing Troponin I-immunoreactivity. Cells 
were postfixed with 2.5% glutaraldehyde (15 minutes) and 1% osmium tetroxide 
(30 minutes). The samples were dehydrated and embedded in Epon. Ultrathin 
sections were examined with a Jeol 1200EX electron microscope (Jeol USA, 
Paabody, MA). 
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Table 3. List of primary antibodies used in immunocytochemical studies. 
 
 
 
Marker type Antibody Origin Dilution rate Supplier 
Pluripotency OCT3/4 goat 1:300 af1759,R&Dsystems 
Pluripotency Nanog goat 1:200 af1997,R&Dsystems 
Cardiac Troponin I goat 1:500 SC8118,Santa Cruz Biotech 
      Cardiac Troponin T mouse goat 
1:500 
1:1500 
ab33589, Abcam 
ab64623, Abcam 
Cardiac α-actinin (sarcomeric) mouse 1:1500 A7811, Sigma 
Cardiac(ventricular) ventricular- MHC  mouse 1:100 
mab1552, Chemicon 
 
Cardiac (atrial) MLC-2a mouse 1:300 311 011, SynapticSystems    
Cardiac progenitor Isl-1 mouse 1:500 DSHB  
Mesoderm Brachyury T rabbit 1:100 ab20680, Abcam  
Endoderm α -fetoprotein (AFP) goat 1:100 SC8108, Santa Cruz Biotech 
Ectoderm Sox1 goat 1:100 SC17318, Santa Cruz Biotech 
Ectoderm Pax 6 mouse 1:300 DSHB 
Gap junction Connexin 43 mouse 1:1500 mab3068, Chemicon  
Gap junction Connexin 40 rabbit 1:1000 ab1726, Chemicon  
Proliferative cells Ki67 rabbit 1:800 ab9260, Chemicon  
 53
4.7 Electrophysiological methods 
4.7.1 Patch clamp (IV) 
In Study IV, action potentials (APs) were recorded from dissociated beating cells 
using the whole-cell configuration of the patch-clamp technique with an Axopatch 
200B amplifier (Molecular Devices, Sunnyvale, CA, USA) and data acquisition and 
analysis was performed with pClamp 9.2 software (Molecular Devices). A coverslip 
with the adhering cells was placed in the recording chamber and perfused with 
extracellular solution consisting of 143 mM NaCl, 4 mM KCl, 1.8 mM CaCl2, 1.2 
mM MgCl2, 5 mM glucose, 10 mM HEPES (pH 7.4 with NaOH; osmolarity 
adjusted to 301 ± 3 mOsm). The osmolarity was measured with an Osmostat OM-
6020 osmometer (DIC Kyoto Daiich Kagagu Co. Ltd, Japan). Patch pipettes were 
pulled from borosilicate glass capillaries (Harvard Apparatus, Kent, UK) and had 
resistances of 1.5 to 3 MΩ when filled with a solution consisting of 130mM KCl, 7 
mM NaCl, 1 mM MgCl2, 5 mM Na2ATP, 5 mM EGTA, 5 mM HEPES (pH 7.2 with 
KOH; osmolarity adjusted to 290 ± 3 mOsm). 
To measure calcium currents the extracellular solution consisted of 137 mM 
TEA-Cl, 5.4 mM CsCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 5 mM HEPES 
(pH 7.4 with TEA-OH; osmolarity adjusted to 298 mOsm) and the intracellular 
solution consisted of 115 mM Cs methanesulfonate, 20 mM CsCl, 2.5 mM MgCl2, 2 
mM MgATP, 11 mM EGTA, 10 mM HEPES (pH 7.2 with CsOH; osmolarity 
adjusted to 273 mOsm). These recordings were undertaken in voltage-clamp mode 
with cell capacitance and series resistance compensated the latter by ≥70%. Calcium 
currents were elicited from a holding potential of –60 mV by 500 ms voltage steps 
from -50 to +40 mV.  
Noradrenaline (Research Biochemicals Inc., Natick, Ma, USA) and E-4031 
(Alomone Labs, Jerusalem, Il) were dissolved in water while veratridine (Sigma, St 
Louis, MO, USA) was dissolved in dimethyl sulphoxide, all to obtain stock 
solutions of 10 mM from which the final concentrations were prepared daily by 
dilution with extracellular solution. Experiments were conducted at 35.7 ± 0.1°C. 
The concentrations of the drugs were: 100 nm noradrenaline, 100 nM E-4031 
(selective hERG inhibitor) and 10 μM veratridine. 
4.7.2 Microelectrode array (II) 
The electrical activity of dissociated beating cells was monitored using the Micro 
Electrode Array (MEA) system (Multi Channel Systems MCS GmbH, Reutligen, 
Germany). Dissociated cells were plated on FBS and gelatin coated MEA chambers 
(type: 500/30iR-Ti) and measurements were done at +37ºC. Signals were recorded 
for four minutes via every microelectrode. The sampling frequency was 20 kHz, and 
the signal frequency band was limited to 1 Hz – 8 kHz.  
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Chronotropic response characterization was performed using dissociated beating 
cells. The twenty-two-day-old cells were in a MEA chamber for 14 days before the 
addition of the pharmacological agents. The effect of verapamil, a specific L-type 
Ca2+ channel blocker (Verpamil, Orion, Espoo, Finland), was tested at a 
concentration of 5 μM (2.5 µg/ml). To increase the beating rate, a β-adrenoreceptor 
system activator, isoprenaline (Isuprel, SA Abbot NW, Ottignies, Belgium), was 
added 0.07 μM (0.017 µg/ml) to the cells. Finally, a cardioselective β-antagonist, 
esmolol (Breviblock, Baxter Healthcare Group, Deefield, IL, USA) at 
concentrations of 0μM, 43μM or 75 μM (0 µg/ml, 14.3 µg/ml, or 25.0 µg/ml) was 
tested without washing off the isoprenaline.  
4.8 Statistical Analysis (I-IV) 
From EB size analysis (I), qPCR (II and III), differentiation efficiency (III) and 
electrophysiological measurements (IV) the data is given as mean ± standard 
deviation (SD) of experiments. The statistical significance was ascertained using 
either one-way ANOVA test with Bonferroni correction or by the Student’s t-test. 
The statistical analysis was performed with SPSS software (version 14-17) (SPSS 
Inc., Chicago, IL, USA). 
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5. Results 
5.1 Analysis of undifferentiated pluripotent stem cells (I-
IV) 
Before differentiation, the undifferentiated state of pluripotent stem cells was 
verified by visual observation and by the expression of the pluripotency markers. In 
the Study III, after prolonged adaptation of H7 line to the hFF feeders, the 
expression level of germ layer markers (Brachyury T, AFP and Sox1) was elevated. 
Nevertheless, according to the immunocytochemistry, the cell colonies of these lines 
were still positive for pluripotency markers. 
All hESC lines had a normal karyotype but iPS cell line h1/06 had an inversion on 
chromosome 12.  
5.2 Spontaneous differentiation in embryoid bodies (I) 
5.2.1 Formation and growth of embryoid bodies 
The EB formation was performed by the similar method as for the hESC 
passaging, i.e. mechanical cutting of hESC colonies. The EBs were allowed to form 
in the U-shaped, low attachment, 96-well plate wells for seven days. In addition to a 
round-shaped EB, a thin cell layer formed on the bottom of the wells. On day 7, the 
EBs formed were transferred and allowed to attach to the gelatine coated cell culture 
plates. 
The cross-sectional area (mm2) of the forming EBs was determined for the first 
seven days of differentiation. The area of the EBs increased significantly during this 
time period in all the hESC lines studied (Study I, Table 1). After plating, the size of 
the original EBs did not change but rather asymmetric three dimensional outgrowth 
structures originating from them were formed. In addition, a layer-like structure 
formed finally covering (> 35 days) the whole 12-well plate well. No relevant 
differences in the EB morphology between hESC lines were observed before plating 
onto gelatine, but thereafter there was considerable variation in the cell proliferation 
and growth of the EBs (Study I, Supplementary Figure 2). Some hESC lines formed 
thick cell layers and outgrowths whereas some did not grow at all, only forming a 
thin cell layer on the bottom of the cell culture well. Occasionally three-dimensional 
cystic structures started to occur after plating to gelatine. Beating areas were 
observed only in well-growing EBs.  
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5.2.2 Pluripotency, germ layer and differentiation marker 
expression during embryoid body development 
 
Protein expression in the tissue sections from the differentiating EBs was 
assessed by immunocytological stainings with pluripotency marker Oct4, with 
different germ layer markers (mesodermal Brachyury T, endodermal AFP and 
ectodermal Sox1) and with the cardiac lineage marker Nkx2.5. Because fragmented 
nuclei were seen in many developing EBs (Figure 7), caspase-3 staining was 
performed to assess apoptosis in the developing EBs. Additionally, RT-qPCR was 
used to assess the mRNA expression levels of the same markers and to confirm the 
immunocytochemical data, Oct4 and Brachyury T were also studied by Western blot 
analysis.  
The protein expression of Oct4 started to decrease after the initiation of EB 
differentiation, but it was occasionally still clearly visible on day 8 or 10 and was 
also present in some EBs even on day 12 (Study I, Figure 1 and Supplementary 
Figure 4). Generally the staining decreased regularly from day 8. The expression 
could be seen in the middle of the EBs as well as on the edges of EBs (Figure 7). 
Overall, the expression pattern for Oct4 was similar in all the hESC lines studied. 
Western blot analysis confirmed that Oct4 was present at all time points studied, 
decreasing only on day 20. At the mRNA level, Oct4 was strongly expressed in the 
undifferentiated cells and the amount decreased so that on day 20 the expression 
level was very low.  
The protein expression of Brachyury T was remarkably low in all the EB 
sections. Sparse stained cells were detected between days 4 and 12 in most of the 
EBs, while there were several Brachyury T stained-cells in only a few sections 
(Study I, Figure 3). Unexpectedly, hardly any Brachyury T positive cells were seen 
in the hESC line with the best differentiation efficiency (HS346). Confirmation of 
the protein expression of Brachyury T by Western blot showed fairly low expression 
at all time points (Study I, Figure 2). Brachyury T gene expression increased during 
the first week of differentiation and reached its highest level on day 7, decreasing 
steadily thereafter (Study I, Figure 2). 
AFP protein was present in EBs of all ages. AFP protein expression was sporadic 
in some samples and abundant in others, but did not correlate with EB age or the 
hESC line (Study I, Figure 3). AFP staining was already detected on day 4 and did 
not markedly increase over time. AFP was expressed both in the middle and on the 
periphery of EBs (Figure 7). Expression was not clearly overlapping with Sox1 or 
Brachyury T but in the multiple EBs the same areas and even overlapping cells were 
labelled for AFP and Oct4 (Figure 7). AFP gene expression was detected on day 3 
and was most highly expressed on day 20 (Study I, Figure 2). 
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Figure 7. Oct4 and AFP protein expression in EB (brown arrows). Oct4 was partly 
overlapping with AFP. Fragmented nuclei were seen in many EBs (blue arrow). Scale bar 
50µm. 
Sox1 protein expression could first be detected in 4 to 6-day-old EBs as single 
positive cells (Study I, Figure 3). Clear positive areas were seen in the EBs from day 
8 onwards. Some differences in the amount of Sox1 could be detected between the 
lines. The strongest positive staining was seen in HS362 and HS181 lines. In HS181 
a small number of immunoreactive cells were already detected on day 4. In the 
hESC lines with the highest cardiac differentiation potentials, such as HS346, Sox1-
positive cells were sporadic and no clearly positive areas were detected. The 
labelled areas did not overlap with any other germ layer marker or with Oct4 and the 
positive areas were located both at the edges of the EBs and in the middle of them. 
At the mRNA level, Sox1 was also most abundant around day 20 (Study I, Figure 
2). 
Protein expression of cardiac lineage marker Nkx2.5 was already detected in a 
few cells in the 4-day-old samples and the expression continued until day 12. No 
differences between hESC lines were observed (data not shown). Nkx2.5 gene 
expression increased during the first week and peaked around day 11 (Study I, 
Figure 2). 
Caspase-3 immunoreactivity was observed throughout the study period. At the 
initial stage of EB development, staining was seen in the inner parts of EBs (Study I, 
Figure 4). In the older EBs caspase staining was not so intense and at the same time 
cavities begin to occur inside the EBs. However, caspase-3 labelling or cavity 
formation was not seen in all EBs (Study I, Figure 4 and Supplementary Figure 4). 
The cavity formation was not specific to any hESC line or age of EBs. 
Older beating and non-beating aggregates (aged 30 to 60 days) were stained with 
Oct4, Brachyury T, Sox1, AFP, cardiac troponin T (cTnT), Pax6, and Nkx2.5 
antibodies. Single Brachyury T-positive cells but no Oct4 or Sox1-positive cells 
were detected in these older aggregates (data not shown). Obvious distinct areas 
containing AFP, cTnT, and Pax6-immunoreactive cells were detected in beating 
aggregates (Study I, Figure 5). If no beating was detected, no cTnT positive cells 
could be observed either. AFP staining was relatively abundant and co-localized 
with cTnT-positive areas in some of the EBs but AFP also stained areas that were 
not cTnT-immunoreactive. Ectodermal Pax6 -positive cells formed separate areas 
without overlapping with other markers. Early cardiac marker Nkx2.5 was 
expressed sporadically and partly overlapped with cTnT-immunoreactive area. The 
size of the beating areas varied considerably between samples, some areas 
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containing only tens while others contained hundreds of cells. Clear striated patterns 
in the cells could be seen with cTnT staining (Study I, Supplementary Figure 5). 
5.3 Differentiation in mouse visceral-endoderm-like cell 
co-cultures (II and III) 
5.3.1 Morphology of differentiating cell aggregates (II) 
The morphologies of the undifferentiated colonies of all eight hESC lines were 
similar. However, when differentiated, cell lines with good or intermediate cardiac 
differentiation efficiency formed more compact three dimensional structures on 
END-2 cells when compared to lines with lower efficiency (Study II, 
Supplementary Figure 1). This concurs with earlier results, as sharp-edged three 
dimensional structures have been reported to be conducive to the formation of 
beating areas (Passier et al., 2005).  
5.3.2 Pluripotency, germ layer and differentiation marker gene 
expression levels during mouse visceral-endoderm-like 
cell co-culture 
To investigate the gene expression of germ layer markers in lines HS181, HS293, 
HS346 and HS368, the mRNA levels of differentiation and germ layer markers were 
compared (Brachyury T, MESP1, Nkx2.5, Isl-1, BMP-4, KDR, AFP, Sox17 and 
Sox1) (Study II, Figure 1 and Supplementary Figure 2). Differentiating cell 
aggregates were pooled from four or six 12-well late wells at timepoints of 3 and 6 
days. For every cell line, two cell pools were collected from separate differentiation 
experiments. 
The expression of mesoderm marker Brachyury T was transient, peaking on day 
3 in all four lines (Study II, Figure 1). The highest expression on day 3 was 
observed in HS346 when compared to HS293 and HS181 (p<0.01). The expression 
of cardiac mesoderm marker MESP1 and Brachyury T had similar expression 
patterns. In all lines MESP1 expression was higher on day 3 than on day 6. 
In HS346, the Nkx2.5 mRNA level increased vastly from day 3 to day 6 and was 
more than three times higher on day 6 in HS346 compared to the other lines 
(p<0.00005) (Study II, Figure 1). mRNA levels of Isl-1, a cardiac progenitor 
marker, behaved differently from the other markers reportedly associated with 
cardiac differentiation. On day 3 Isl-1 was significantly more expressed in HS293 
than in the other lines (p<0.0005) (Study II, Figure 1).  
The expression of the mesodermal marker BMP-4 increased in all four lines from 
day 3 to day 6 and KDR, another mesoderm marker, was decreased in HS181, but 
also in HS346 (Study II, Supplementary Figure 2).  
AFP expression increased significantly from day 3 to day 6 in HS293, HS346 
and HS368 (p<0.05) similarly as was observed with HS181 cells. The expression of 
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another endodermal marker Sox17 did not differ between the four lines (Study II, 
Supplementary Figure 2).  
The expression of the ectoderm marker Sox1 was lowest in HS346 on both day 3 
and 6 and highest in HS181. There was also a significant difference in the 
expression of Sox1 between HS293 and HS346 on day 6 (p<0.05) (Study II, 
Supplementary Figure 2). 
The expression of pluripotency marker Oct4, germ layer markers (Brachyury T, 
AFP, Sox1) were also evaluated during END-2 differentiation with the hESC lines 
Regea 08/017, H7 and iPS cell line h106 (Study III, Figure 2). To assess the effect 
of feeder cells on the cardiac differentiation, these lines were cultured both on hFF 
and MEF feeder cell layer.  
 Mesodermal marker Brachyury T expression was significantly higher on day 3 
for H7 cultured on MEF than for H7 cultured on hFF (p=0.021). Similarly, the 
expression was at higher level for Regea 08/017(MEF) than Regea 08/017(hFF) 
(p=0.002). h1/06 behaved differently, having significantly higher expression when 
cultured on hFF than MEF feeders (p=0.001). H7(hFF) had a Brachyury T 
expression peak later if compared to H7(MEF)  day 6 (Figure 8). A similar kind of 
expression curve was seen for Regea 08/017(MEF), having still relatively high 
expression at the same time point (Study III, Figure 2).  
 
 
 
Figure 8. Brachury T mRNA levels during END-2 co-culture for H7 cultured on human 
feeder cells (hFF) (open circles) and cultured on mouse feeder cells (MEF) (closed circles). 
Expression peak for H7(hFF) is delayed when compared to H7 (MEF cultures. Expression 
difference was significant between samples as marked with *. 
 60 
5.4 Cardiomyocyte differentiation efficiency (I, II, III) 
In the Studies I and II, cardiac differentiation was performed with the same cell 
lines and by two differentiation methods. The differentiation efficiency varied 
between hESC lines with both the methods used. Overall, the efficiency was 
relatively low, the HS346 formed beating areas with the highest efficiency rate of 
9.4% in END-2 co-cultures and 12.5% with EB differentiation. The line HS293 did 
not form any beating areas with either of the differentiation methods. The 
differentiation efficiencies are summarized in Table 4. Substantial variation in 
cardiac differentiation within individual lines was also observed, but this variation 
did not correlate with the passage number.  
 
 
Table 4. Cardiac differentiation efficiency of hESC with END-2 co-culture and EB- 
method. 
  
Cell line Karyotype 
END-2 
Differentiation efficiency % 
(total number of beating areas/ 
total number of cell 
aggregates) 
EB 
Differentiation efficiency 
% 
(total number of beating 
areas/ total number of 
EBs) 
HS181 46 XX 2.9 (18/625) 1.6 (3/192) 
HS237 46 XX 2.7 (13/480) n.a 
HS293 46 XY 0 (0/420) 0 (0/192) 
HS346 46 XX 9.4 (299/2433) 12.5 (24/192) 
HS360 46 XY 1.5 (7/480) 1.0 (2/192) 
HS362 46 XY 3.2 (11/349) 2.1 (4/192) 
HS368 46 XY 4.8 (46/968) n.a 
HS401 46 XY 2.8 (24/867) 7.3 (14/192) 
Regea 06/015 46 XY 3.3 (21/629)* 7.3 (14/192) 
Regea 06/040 46 XX 5.1 (41/800)* 12.0 (23/192) 
*(Pietilä, 2008) 
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In the Study III, the cardiac differentiation potential of three lines (H7, Regea 
08/017 and iPS cell line h1/06) cultured on both hFF and MEF feeder cells was 
compared. The H7 line had the highest differentiation rate and also the iPS cell line 
h1/06 formed more beating areas than the Regea 08/017 line. The number of 
Troponin T positive cells was significantly higher for H7(MEF) (36 122 cells) than 
H7(hFF) (14 482 cells) (p=0.008). For Regea 08/017 the number of cells in total and 
Troponin T positive cells was notably lower than for H7. In addition, the number of 
Troponin positive cells was slightly but not significantly higher for MEF (2 226) 
than for hFF (1 024) cultures (p=0.087). The differentiation data of this study is 
summarized in Table 5.  
 
Table 5. Summary of the differentiation data of the lines Regea 08/017, H7 and iPS 
cell line h1/06. * The total number of cell aggregates could not be precisely 
determined. Therefore the estimation, 30 cell aggregates, was used to determine 
the differentiation efficiency. 
 
Cell line Regea 08/017 H7 h1/06 
Feeder type MEF hFF MEF hFF MEF hFF 
Average number of 
beating areas/well 0.84 0.17 3.4 0.67 1.4 0.83 
Differentiation 
efficiency % (total 
number of beating 
areas / total number of 
cell aggregates)  
2.53* 0.56* 11.28* 2.22* 4.54* 2.78* 
Average number of 
Troponin T positive 
cells/ in a well 
(SD) 
2 226 
(381) 
1 024 
(585) 
36 122 
(7023) 
14 482 
(7023) 
9 021 
(4014) 
6 766 
(1460) 
5.5 Characterization of the differentiated cells (I-IV) 
5.5.1 Expression of cardiac specific genes (II) 
Differentiated cells expressed cardiac marker genes such as α- myosin heavy 
chain, atrial myosin light chain, ventricular myosin light chain, cardiac troponin T, 
GATA-4, and connexin-45 at levels comparable to commercial adult heart RNA 
(Study II, Supplementary Figure 3). 
5.5.2 Structural characteristics (II) 
In electronmicroscopy, the cardiac cells showed a variable degree of 
differentiation. In a large number of cells, bundles of myofibrils could be seen 
(Figure 9). In most of the cells bundles were randomly distributed, however in some 
cells, clearly differentiated sarcomeres with Z lines were seen (Figure 9). 
Intercalated discs were also seen between adjacent cells. Cells contained several 
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mitochondria, which were often situated close to sarcomeres and numerous 
polyribosomes. In addition, immunoelectron microscopy revealed troponin I-
immunoreactivity in the myofibrils (Study II, Supplementary Figure 4). 
 
Figure 9. Electon microscopy figure of the hESC-CM. In the electron microscopy clearly 
differentiated sarcomere structures (arrowheads) with Z lines (arrows) could be seen. 
5.5.3 Expression of cardiac specific proteins (I-IV) 
The differentiated cardiac cells stained positively with several cardiac markers, 
including cardiac α-actinin, cardiac troponin T and I, ventricular α-myosin heavy 
chain, myosin light chain A, connexin-43 and connexin-40 (Figure 10). Connexin-
43 and 40 were localized between the actinin or troponin positive cells, indicating 
that the beating cells have gap junctions between them. According to 
immunostaining with a Ki67 antibody (a marker for proliferating cells) some of the 
cardiac α-actinin positive cells were in the cell cycle. In addition, cTnT staining 
revealed a striatern pattern indicating sarcomere structures. 
 
Figure 10. Characterization of differentiated and dissociated cells by immunocytochemistry. 
A-B Cardiac Troponin T (cTnT) (red) and nuclei stain dapi (blue), C cTnT (red), ventricular 
α-myosin heavy chain (green) and dapi (blue), D-F cTnT (red), α-myosin heavy chain 
(green) and dapi (blue), G-I cardiac α-actinin (red), Ki67 (green) indicating cardiac α-actinin-
positive cells that are still in the cell cycle and dapi (blue), J-L cTnT (red), myosin light chain 
A (green) and dapi (blue), M-O cTnT (red), connexin 43 (green) revealing gap junction 
structures between the Troponin T positive cells, and dapi (blue) P-R cTnT (red), connexin 
40 (green) again revealing gap junction structures between the Troponin T positive cells 
and dapi (blue). Differentiated beating cells have a striatern pattern typical for sarcomeric 
structures (A and B). 
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5.5.4 Functional characteristics of the differentiated cells (II and 
IV) 
5.5.4.1 General action potential properties of human embryonic stem cell- 
derived cardiomyocytes (IV) 
The basic electrical properties of cardiomyocytes obtained from different hESC 
lines were very similar and thus the results from different lines were pooled. The 
spontaneous electrical activity of hESC-CMs mostly exhibited a continuous pattern 
where AP rates were relatively constant throughout the recording period, with 
frequencies ranging from 24 to 156 beats per minute (bpm), mean 72 ± 6 bpm (0.4 – 
2.6 Hz, mean = 1.2 ± 0.1 Hz). EB-derived cardiomyocytes were slightly more 
homogeneous since 97% of them were beating continuously, while 89% of END2-
derived cardiomyocytes exhibited continuous firing pattern. The remaining hESC-
CMs displayed firing patterns either of more than one frequency or episodic in 
nature (Study IV, Figure 2).  
Based on the AP morphology and parameters, such as AP duration at 90% 
repolarization (APD90), maximum rise of the AP upstroke (dV/dtmax), AP amplitude 
(APA) and maximum diastolic potential (MDP), the AP phenotype was classified as 
nodal-like, atrial-like or ventricular-like. Atrial-like APs were defined as those with 
triangular in shape whereas those APs with a significant plateau phase were 
categorized as ventricular-like (He et al., 2003b, Cao et al., 2008). None of the APs 
(from 69 hESC-CMs patched) fulfilled the criteria adopted for classification as 
nodal-like i.e. slow upstroke, prominent phase 4 depolarization, relatively 
depolarized MDP and small APA. Atrial-like APs were few as ventricular-like 
predominated (Study IV, Table 1), distinguished respectively by their triangular 
shape and significant plateau phase (Study IV, Figure 4). The  beating rate of atrial-
like cardiomyocytes was on average 48/min while the rate of ventricular-like 
cardiomyocytes was on the average 78 at least partly explaining the observed longer 
AP duration in atrial-like cardiomyocytes versus ventricular-like APs. All the atrial-
type cardiomyocytes were obtained by END-2 differentiation method, while none of 
the EB-derived cardiomyocytes demonstrated atrial-like AP. The prevalence of 
ventricular type cardiomyocytes was 80% (28/35) and 100% (34/34) with END-2 
and EB differentiation methods respectively. 
Within the ventricular-like AP category there was heterogeneity in AP shapes 
and properties (Study IV, Figure 4). For instance the dV/dtmax ranged from 15.8 to 
302.5 V/s. The APs exhibiting a fast upstroke (dV/dtmax≥200V/s) were associated 
with a significantly more hyperpolarized MDP compared to APs with low upstroke  
(dV/dtmax≤100V/s). The average MPD was less than -70 mV ranging from -55 mV 
to over -80 mV. The dV/dtmax was similar whether differentiation was via END-2 
co-culture or spontaneously within the EB and between the various times in culture 
(Study IV, Figure 5). A difference was evident between the differentiation methods 
in terms of the MDP with the EB groups exhibiting a significantly more 
hyperpolarized MDP. Time in culture had no effect on MDP. For APD90 it appeared 
the culture time was a factor, though not significant, with the longest time for each 
differentiation method giving rise to shorter APD90 values.    
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5.5.4.2 Human embryonic stem cell derived cardiomyocytes as cellular models of 
QT prolongation and proarrhythmia (IV) 
Addition of the selective hERG inhibitor E-4031 resulted in a marked 
prolongation of the hESC-CM AP (Study IV, Figure 6), especially for phase 3 as 
evident from the greater effect on APD90 compared to APD50. Such slowing of 
repolarization leads to triangulation of the AP. APD90 prolongation was also 
observed with the inhibition of sodium channel inactivation by veratridine, which 
mimics the sodium current (INa) defect of congenital LQT3 and is another 
mechanism for drug-induced QT prolongation (Milberg et al., 2005). Furthermore 
the APD90 evolved from changes between APs in control, with E-4031 exposure, to 
successive lengthening and later to deviation from unity as successive large changes 
occur, corresponding to beat-to-beat variability i.e. APD instability.  
The presence of the L-type Ca2+ current and EADs during prolonged E-4031 
exposure in hESC-CMs was readily demonstrable. Another form of triggered 
activity, delayed afterdepolarizations, which take place after full repolarization, 
occurred on occasion spontaneously. 
5.5.4.3 Chronotropic response of human embryonic stem cell-derived 
cardiomyocytes (II and IV) 
Chronotropic response of hESC-CM was monitored with dissociated beating 
cells with the micro-electrode array (MEA) (Study II, Figure 3). Beating in the 
cardiomyocyte culture ceased approximately two minutes after the adding of 5 μM 
verapamil. Thereafter, the culture was washed with medium, and a resumption of 
consistent beating was observed both visually and electrically. Adding 0.07μM 
isoprenaline increased the average beating rate (ABR) by about 50% and this effect 
could be reversed by adding esmolol in a dose dependent manner. After the 
measurements, the culture was washed, and the reversibility of the drug effects was 
confirmed. According to on the MEA measurements, we also observed conduction 
of electrical activation between beating colonies. 
Patch clamp studies revealed increase in the frequency of AP firing after 
exposure of hESC-CMs to noradrenaline (Study IV, Figure 3), concomitant with 
which was an increase in the diastolic depolarization rate and a decrease in AP 
duration. 
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6. Discussion 
The aim of present thesis was to evaluate the differentiation of pluripotent stem cells 
(hESC and iPS cells) to cardiomyocytes and to characterize the differentiated cells. 
In addition, the differentiation potential of several hESC lines cultures on mouse and 
human feeder cells was evaluated. Differentiation was performed by two 
differentiation methods and in addition to multiple molecular biology 
characterization methods, the electrophysiological properties of differentiated 
cardiomyocytes were determined. 
Pluripotent stem cells can be differentiated into functional cardiomyocytes, even 
though the differentiation potentials of cell lines differ from each other. Overall, the 
differentiation rate of the hESC lines used was low. However, commercially 
available line H7 differentiated more effectively likewise human iPS cell line 
derived in our laboratory. Differentiated cells from all the lines used were beating 
spontaneously and expressed specific cardiac markers.  
6.1 Evaluation of cardiac differentiation capability of 
pluripotent stem cell lines (I-III) 
In the Studies I-III the cardiac differentiation potential of several individual 
hESC lines and one human iPS cell line was evaluated and compared. The cardiac 
differentiation was performed using the END-2 co-culture and spontaneous 
differentiation method in EBs. Some of the lines were clearly more efficient than 
others in forming beating areas, but variation in cardiac differentiation potential 
within individual lines was also observed. One of the hESC lines, HS293, 
completely lacked the ability to form beating areas. 
In the Studies I and II considerable variation was found in cardiomyocyte 
differentiation between hESC lines derived in the same laboratory and maintained 
with similar culturing and passaging methods. The differentiation efficiencies of the 
hESC lines used ranged from 0% to 9.4% in END-2 co-culture and 0% to 12.5% in 
EBs. The variation between lines was uniform with both of the differentiation 
methods used. It is noteworthy that line HS293 did not form beating cells with either 
of the differentiation methods. A similar finding was reported earlier with EB 
differentiation; hESC line hES2 (NIH code ES02) failed to produce beating areas 
spontaneously. However, this line produced cardiomyocytes when differentiated in 
co-culture with END-2 cells (Mummery et al., 2003, Moore et al., 2008).   
 Variation in the differentiation potential of individual hESC lines and iPS cell 
lines has been reported in numerous studies (Lee et al., 2005, Mikkola et al., 2006, 
Kim et al., 2007, Zhang et al., 2009). In addition, hESC-CM differentiation has been 
analyzed in many reviews comparing individual studies (Devine et al., 2001, 
Mummery, 2007), but usually only one hESC line has been used in the study (Xu et 
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al., 2002, He et al., 2003a, Pal and Khanna, 2007). The cardiac differentiation 
efficiency in these studies has varied enormously (8.1%-70%). In a recent report of 
17 individual hESC lines (Osafune et al., 2008) the variation in cardiac 
differentiation potential was analyzed by comparing the expression levels of cardiac 
markers (Nkx2.5 and cTnT). The percentage of EBs containing cells positive for 
either cardiac marker was 10% (for the cell line with the lowest differentiation 
efficiency) and 44% (for the line with the highest differentiation efficiency), while 
the frequency of beating EBs was only 2.9% and 13.6% respectively (Osafune et al., 
2008).  
Another study compared the cardiac differentiation of four different hESC lines 
derived in three different laboratories and maintained with two different passaging 
methods (Burridge et al., 2007). The percentage of beating EBs varied between 
1.6% and 9.5%. and the authors concluded that the variation was due to derivation 
in different laboratories (Burridge et al., 2007). Our results differ from these results. 
All our hESC lines were derived in the same laboratory and six of them were 
initiated with the same derivation method (Hovatta et al., 2003). Two of the lines 
(HS181 and HS237) were derived in FBS, but then transferred to serum replacement 
medium. Culture conditions cannot explain the differences either, since the all cells 
lines were cultured and passaged identically. It is noteworthy that HS293 (which 
lacked the ability to form beating cells) and HS346 (the line with the highest 
differentiation efficiency) were derived using exactly the same method, but showed 
the greatest difference in their cardiac differentiation potential.  
The estimation and comparison of differentiation efficiencies is problematic, 
especially with END-2 co-culture, due to the technical dissimilarities between 
different laboratories. When undifferentiated hESC colonies were dissociated 
mechanically, in the present study the number of beating areas per total number of 
cell aggregates plated onto END-2 cells was compared. However, some of these 
aggregates are lost during medium change because they do not attach to the bottom 
of the cell culture well. One solution to this would be to count the attached cell 
aggregates after a few days of plating. This is very laborious and also rather difficult 
because some of the aggregates may be attached to each other, form flat cell areas 
on the bottom of the well or grow so that is impossible to accurately count the cell 
areas. For these reasons, to standardize differentiation 15 cell colony pieces were 
plated onto END-2 cells and this number was used in estimation the differentiation 
efficiency in the Study II.  
In Study III another approach was used in the dissociation of undifferentiated cell 
colonies. Cell colonies were dispersed either by cell scraper or by scalpel because 
the enzymatically passaged undifferentiated cell colonies were much thinner making 
the cutting of colonies impossible. The colony pieces were not similarly sized and 
the cell suspension also contained smaller cell colony pieces and even single cells in 
addition to pieces similar to those used in Study II. Therefore the number of plated 
cell colony pieces could not be quantified as precisely as when the cell colonies 
were cut into pieces. To enable comparison of differentiation efficiencies between 
Studies II and III, the efficiencies were counted using the number of large cell 
colony pieces (30 cell pieces) to determine differentiation efficiency. However, a 
similar number of colonies were plated onto END-2 cells for all the six cell lines 
used in Study III and the differentiation efficiency was determined by the average 
number of beating areas per 12-well plate well. In addition, the percentage of 
troponin T positive cells from the total number of cells was determined.  
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The differentiation in co-culture with END-2 cells as originally described by 
Mummery and co-workers (Mummery et al., 2003) was reported to produce on 
average 32.7 beating areas per 12-well plate (2.7 beating areas per well) and 
corresponding to 16 600 cardiomyocytes (Passier et al., 2005). Since the starting 
numbers of cells was not stated in their work a comparison of results is difficult as 
discussed above. It is, however, evident that we could not achieve corresponding 
differentiation efficiencies with HS hESC lines and Regea lines. The best 
differentiation efficiency (HS346) was 9.4% corresponding to 17 beating areas per 
12-well plate and 1.4 per well. The corresponding numbers for Regea 08/017 line 
cultured on hFF feeder cells were 0.56% corresponding to 2.04 beating areas per 12-
well plate, 0.17 beating areas/well and 1024 cardiomyocytes/well. By contrast, H7 
differentiated most efficiently on END-2 cells in the present study, having an 
efficiency of 11.28%, forming 3.4 beating areas per well. The number of 
cardiomyocytes was also in line with the report by Passier and co-workers 
mentioned above, H7 line formed 36 122 cardiomyocytes per well (3.3 % troponin 
T positive cells in a well of 1 100 000 cells in total).   
 Passier and co-workers reported a wide variation in the number of cells in the 
beating areas, ranging from 1-2500 cells (Passier et al., 2005). Therefore the number 
of beating areas per plated cell aggregates might give misleading results about the 
differentiation efficiency. Cytospin analysis has been used in the estimation of 
percentage of cardiac marker positive cells per total number of cells (Graichen et al., 
2008, Xu et al., 2008a). This method gives a more accurate number of differentiated 
cells but unfortunately has its own weaknesses. Before spinning the cells to the class 
slides the cells have to be enzymatically dissociated into single cell stage. Older co-
cultures especially contain solid cell aggregates which cannot be dissociated 
thoroughly and some cell aggregates remain and are lost before staining and 
analysis. 
One major difference between many other cardiac differentiation reports and the 
present study is that here hFFs were used as feeder cells for hESC while others have 
used MEFs. Therefore we evaluated whether the culturing on MEF feeders 
increased the cardiac differentiation rate. The Regea 08/017 usually maintained on 
hFF feeder cells was also adapted to be cultured on MEF feeders and hESC line H7 
and iPS cell line were adapted to be cultured on hFF feeders in addition to MEFs. 
Indeed, the adaptation and culturing on MEFs increased the differentiation rate of 
Regea 08/017 line slightly but not significantly. However, the differentiation 
efficiency of H7 was decreased with statistical significance after hFF culturing. The 
number of troponin T positive cells decreased from 36 122 MEF cultures to 14 482 
on hFF. Therefore it can be suggested that feeder cells affect the differentiation 
efficiency.  
Activin A may be one key factor affecting this phenomenon, as it is reported to 
be expressed at higher levels from MEF than hFF feeder cells (Eiselleova et al., 
2008) and furthermore it is used in cardiac differentiation protocols (Laflamme et 
al., 2007, Yang et al., 2008). Activin A in combination with BMP-4 induces the 
formation of primitive streak-like population and mesoderm formation (Yang et al., 
2008). Therefore, cells cultured on MEF feeder cells may be more prone to 
differentiate towards mesoderm and further towards cardiac lineage than hFF 
cultured cells. In addition, culturing on MEF feeders may also adapt hESC to mouse 
cells and therefore the plating on END-2 cells does not cause as much stress for the 
cells at the beginning of differentiation. 
 70
The gender and the karyotype of the hESC line have also been thought to play a 
role in determining differentiation capacity (Mikkola et al., 2006, Adewumi et al., 
2007, Pal and Khanna, 2007). An hESC line having an altered karyotype (trisomy 
12, 17 and XXX) has been reported to differentiate normally into cardiomyocytes 
(Pal and Khanna, 2007) while in another study, an altered karyotype was shown to 
affect differentiation in general (Mikkola et al., 2006). Neither gender nor karyotype 
can explain our results. We used both XX and XY cell lines with no correlation with 
cardiac differentiation potential. In addition, the karyotypes of our hESC lines were 
checked regularly and found to be normal. The iPS cell line h1/06 had an abnormal 
karyotype (inversion in chromosome 12) but the line differentiated normally into 
beating cells. 
Our results support the suggestion that in addition to the culturing conditions, 
individual cells of the inner cell mass are the most critical factor for the basic 
differentiation capacity. Mechanical splitting of a single inner cell mass has been 
reported to produce multiple embryonic stem cell lines with dissimilar 
differentiation capacities (Lauss et al., 2005). Furthermore, two hESC lines have 
been shown to differ in their gene expression profiles of mesoderm and early cardiac 
markers at the undifferentiated state, but after cardiac differentiation both expressed 
cardiac markers and engrafted into mouse myocardium (Tomescot et al., 2007). In 
our cell lines the basal expression levels of germ layer markers were undetectable or 
low and did not differ between the lines. Thus, our results confirm the earlier report 
that basal germ layer expression levels do not explain the variation in differentiation 
potential. However, the expression of differentiation markers in the line H7 was 
higher after adaptation and culturing on hFF feeders. This may be due to the 
inefficiency of hFF feeders to maintain the pluripotent state of H7 compared to MEF 
feeders. The line 08/017 maintained the low expression of differentiation markers. 
The differentiation of H7 occurred at the stage where elevated expression was not 
yet seen, so therefore the effect of elevated differentiation marker expression on 
differentiation cannot be presumed. 
The differentiation of human iPS cell line h1/06 emulated the differentiation of 
hESC lines. Differentiation efficiency was at a similar level, beating areas occurred 
on the same timescale and were morphologically alike. This is consistent with 
earlier reports where iPS cells have been differentiated to cardiomyocytes with 
END-2 and EB method (Zhang et al., 2009, Zwi et al., 2009, Freund et al., 2010). 
6.2 Formation and structure of the embryoid bodies (I) 
Many methods have been developed to control the number of cells at the 
initiation of EB formation and to scale up the differentiation process (Zandstra et al., 
2003, Burridge et al., 2007, Bauwens et al., 2008, Niebruegge et al., 2009, Mohr et 
al., 2010). In the present study, enzymatic dissociation in combination with forced 
aggregation (FA) (Burridge et al., 2007) was not successful in producing viable 
EBs. The breaking of hESCs into a single cell stage is usually avoided in hESC 
handling (Thomson et al., 1998, Amit et al., 2000, Kehat et al., 2001, Xu et al., 
2002). The hESC lines used have always been passaged manually and thus these 
lines may be more prone to the stress caused by enzymatic dissociation and 
subsequent centrifugation. Thus, EB formation was commenced by manual 
dissection of hESC, which is a laborious method and may produce more 
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heterogeneous EBs of varying sizes. However, the EBs were cut by the same 
researcher and in fact the size did not vary as much as with the enzymatic method 
(Bettiol et al., 2007, Burridge et al., 2007). The manual method mimics the 
microprinting technique (Bauwens et al., 2008), where the undifferentiated cells are 
at first printed into 2-dimensional colonies with a standard number of cells and then 
detached from the surface to form the three dimensional aggregate. Bauwens and 
co-workers found the status of initial cell population pivotal for cardiomyocyte 
differentiation (Bauwens et al., 2008). This is supported by our finding that the 
individual hESC line is more decisive for cardiomyocyte differentiation efficiency 
than the size of the EBs.  
In addition to the input hESC population, EB size and morphology affect the 
differentiation pathways by influencing the spatial signalling, cell-cell interactions 
or the niche, of the cells. The shape and morphology of the EBs varied considerably, 
but no clear correlation between EB morphology and differentiation patterns was 
seen. However, all the germ layer markers were present in the EBs of all the hESC 
lines studied, but no clear consistent pattern in organization of germ layers was 
observed during these early stages.  
Before the plating of EBs onto cell culture plate, there was no significant 
difference in EB size between the hESC lines. However, at later stages EBs from 
some lines were observed to grow better and looked more viable. Beating areas 
were only seen to form in these well-growing EBs. A similar phenomenon has been 
reported earlier when different culture methods have been used in cardiac 
differentiation. Methods that produced more viable and proliferative EBs also 
produced more cardiomyocytes (Yirme et al., 2008).  
Due to the large number of fragmented nuclei seen in the EBs, caspase-3 staining 
for the samples was performed. Caspase-3, a key player in apoptosis, was already 
expressed in the 2-day-old EBs and continued through all the time period studied. 
Programmed cell death is a fundamental process throughout mammalian 
development (Jacobson et al., 1997) and, interestingly, caspase-3 has been shown to 
be crucial for mouse ES cell differentiation by inactivating nanog (Fujita et al., 
2008). Expression of caspase-3 may also be related to cavity formation, which has 
been reported to occur due to apoptosis inside the EBs (Joza et al., 2001). Cavity 
formation, on the other hand, may be related to the regionalized differentiation of 
hESC (Itskovitz-Eldor et al., 2000, Conley et al., 2004). This is in line with results 
of present study, as cavity-like structures began to occur inside the EBs on day 4. 
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6.3 Expression of pluripotency, germ layer and 
differentiation markers during cardiac differentiation 
(I, II and III) 
Many transcription factors and other proteins controlling germ layer and cardiac 
differentiation could serve as markers for identifying cardiac mesoderm formation 
and developing cardiomyocytes in a differentiating cell cultures. They could also be 
useful in studying the kinetics of differentiation. Hence, we hypothesized that the 
lines, which had a better intrinsic cardiac differentiation capacity, would have higher 
levels of the endoderm and mesoderm/cardiac mesoderm markers expressed during 
early differentiation stages. The expression of these markers was studied at mRNA 
level during END-2 differentiation and at messenger RNA (mRNA) and protein 
level in the EBs. 
Brachyury T is an early mesoderm marker and has been reported to have an 
expression peak at day 3 during cardiac differentiation (Bettiol et al., 2007, 
Graichen et al., 2008, Osafune et al., 2008). Delayed mRNA expression peak of 
Brachyury T has been suggested to indicate the absence of early endodermal and 
mesodermal cell population, which could then lead to poor cardiac differentiation 
(Bettiol et al., 2007). During EB differentiation in our study, the gene expression of 
Brachyury T reached its peak around day 7 being therefore slightly delayed. In 
addition, the protein expression of Brachyury T was surprisingly low in all the 
hESC lines studied and there was no obvious difference in the expression between 
the hESC lines with different cardiogenic potential. Therefore it is possible that all 
our lines (Regea and HS-lines) resemble the poor mesodermal/cardiac lines, with 
low Brachyury T immunoreactivity, as suggested in the earlier report (Kim et al., 
2007). This phenomenon is further supported by the fairly modest cardiac 
differentiation potential of our lines, line (HS346) with the highest differentiation 
efficiency having only about 10 % or less of the EBs with beating areas.  
However, during END-2 differentiation Brachyury T expression was 
significantly induced in the line (HS346) compared to the other lines studied. 
Moreover, Brachyury T expression was higher on MEF cultures than hFF cultures 
of H7 and Regea 08/017 lines which was in line with the cardiac differentiation 
efficiency of these lines. As discussed, delayed Brachyury T expression could 
indicate poor cardiac differentiation ability (Bettiol et al., 2007) and the comparison 
of MEF and hFF feeder cells supports these results. H7 cultured on MEF feeder 
cells, had the highest differentiation efficiency and a sharp Brachyury T peak at day 
3 whereas H7 on hFF gave a wider expression curve peaking later, at day 6, and also 
has less effective cardiac differentiation. Brachyury T expression was also increased 
for Regea 08/017 line after MEF adaptation in line with improved cardiac 
differentiation rate. However, the expression peak was not sharp, staying at the same 
level until day 6. Nevertheless, it can be concluded that Brachyury T expression 
level and the shape of the expression curve could serve as a predictive indicator for 
cardiac differentiation efficiency. 
As the use of END-2 cells in cardiac differentiation indicates, visceral endoderm 
has an important regulatory role in cardiac development (Hosseinkhani et al., 2007). 
In the Study II, the levels of endodermal markers, especially AFP, were low in the 
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best cardiac line, HS346 contradicting to previous findings (Beqqali et al., 2006, 
Bettiol et al., 2007). However, day 6 was the last time point studied and according to 
Studies I and III, the AFP expression was markedly elevated after this time point. 
The expression level of AFP at day 12 for Regea 08/017 line cultured on MEF was 
significantly higher than when cultured on hFF feeder cells and the difference also 
reflected the differentiation efficiency.  
In the EBs, the number of AFP expressing cells was relatively large at all time 
points and, interestingly, some co-localized expression of AFP and pluripotency 
marker Oct4 was detected. Expression of Oct4 in primitive endodermal cells has 
been reported earlier in mouse (Palmieri et al., 1994) as well as induction of 
primitive endoderm differentiation by increased OCT4 expression (Niwa et al., 
2000). Thus it is possible that the endodermal cells in the EBs also expressed Oct4. 
In many older (>30 days) samples AFP was expressed in the vicinity of cardiac 
Troponin T-positive areas suggesting a possible interaction. Whether these areas 
with co-localized Oct4 and AFP protein expression could direct cardiomyocyte 
differentiation cannot be determined.  
Even though the amount of Oct4 protein decreased slowly in the EBs and some 
cells were still positive on day 20, the mRNA level of Oct4 decreased during EB 
and END-2 differentiation rapidly as has been earlier reported (Adewumi et al., 
2007). 
  Ectoderm differentiation was studied with Sox1, which was the only marker 
showing obvious differences in the level of protein expression between the hESC 
lines during EB differentiation. In line HS181, which had relatively poor cardiac 
differentiation capability, Sox1-positive cells were seen in larger amounts during EB 
differentiation when compared to other lines with better cardiac differentiation 
capability. Interestingly, this strongly Sox1-positive line also has a good neurogenic 
differentiation ability (Lappalainen et al., 2010). Similarly, elevated Sox1 
expression of HS181 was seen in END-2 differentiation (Study II). Taken together, 
these results, in combination with others, suggest that certain circumstances could 
support ectoderm or cardiomesoderm formation exclusively. These circumstances 
include medium composition, EB size or the intrinsic differentiation potential of 
individual hESC line (Bettiol et al., 2007, Kim et al., 2007, Graichen et al., 2008, 
Xu et al., 2008a). 
By contrast, Sox1 gene expression does not explain the inability of HS293 to 
differentiate into cardiac cells since it was expressed similarly, at low levels, in 
HS293 and in HS346 (the line with highest differentiation efficiency) in the Study 
II. In addition, H7 had an exceptional expression curve in this respect. Even though 
H7 has the highest cardiac differentiation rate compared to all other lines studied 
here, Sox1 was significantly more expressed in H7 than in other lines during END-2 
differentiation (unpublished data).  
The expression of the cardiac lineage marker Nkx2.5 increases after 4 days of 
differentiation (Graichen et al., 2008, Hsiao et al., 2008) and this was clearly 
observed with both  differentiation methods used in the present thesis. Nkx2.5 
expression was significantly higher in HS346 on day 6 of END-2 differentiation 
when compared to the HS293, indicating more efficient cardiac lineage 
differentiation.  However, at the protein level we saw no correlation with the cardiac 
differentiation capability. Osafune and co-workers have reported that Nkx2.5 
expression could not necessarily determine the cardiac differentiation potential of 
their cell lines (Osafune et al., 2008). In addition, non-cardiac cells have also been 
shown to express Nkx2.5 (Hsiao et al., 2008) which was also supported by our 
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findings because in the older EBs (>30 days), Nkx2.5 overlapped only partly with 
cTnT expressing cells. 
Isl-1 has been suggested to identify a cardiac progenitor population contributing 
to the majority of the cells in the heart (Cai et al., 2003). The expression of Isl-1 was 
unexpectedly highest on day 3 in line HS293, which did not form beating areas. 
However, the difference was no longer significant on day 6. It has been shown that 
Isl-1 expression increases continuously from day 3 to day 12 during END-2 co-
culture (Beqqali et al., 2006) and thus it is possible that our timeframe was not 
sufficient to detect the highest levels in Isl-1 expression for HS293 and HS346. To 
support this, in lines Regea08/017, H7 and h1/06 the Isl-1 mRNA level increased 
after day 6 and reached highest levels at day 12 (unpublished data). The 
characteristics during the END-2 differentiation of the hESC line with a good 
cardiac differentiation potential are summarized in Figure 11. 
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Figure 11. The cardiac differentiation cascade and the characteristics during cardiac 
differentiation in END-2 co-cultures of the hESC line with a good cardiac differentiation 
potential. 
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6.4 Characterization of differentiated cardiomyocytes (I-
IV) 
6.4.1 Molecular and structural characterization 
Multiple molecular biology methods were used in analyzing the beating cells 
obtained from hESC and iPS cells. In addition to the markers for cardiac 
commitment (Nkx2.5 and Isl-1) mentioned above, differentiated cells were 
expressing cardiac specific genes and proteins such as cardiac troponin, α-actinin 
and myosin. Cardiomyocytes were connected to each other via gap-junctions as 
demonstrated by the presence of connexin-43 and 40 between cells. The striatern 
pattern of the cells could be seen with immunocytochemistry similarly in hESC and 
iPS cell-derived cells obtained by both differentiation methods used. 
Organized and clear striatern sarcomeric structure was also evident from the 
presence of Z-bands as seen in electron microscopy. Various degrees of myofibrillar 
organization could be observed, which is characteristic of early stage 
cardiomyocytes (Kehat et al., 2001, Snir et al., 2003). These results indicate that 
regardless of the variation in the differentiation efficiency of hESC and iPS cell 
lines and the differentiation method, differentiated cells share characteristics similar 
to those of functional cardiomyocytes.  
According to immunocytochemistry for Ki-67 (marker for proliferating cells), 
some of differentiated cardiomyocytes were still in the cell cycle and therefore not 
yet fully matured, as has been reported earlier (Snir et al., 2003). The observation 
that cardiomyocytes differentiated in vitro have not matured completely could be 
beneficial for future cell therapy experiments, since the immature cells might 
survive better and could still have the capacity to divide and be influenced by the 
surroundings in the recipient heart (Mummery, 2007). 
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6.4.2 Electrophysiological characterizations  
The differentiated beating cells, in line with earlier studies (Kehat et al., 2002, 
Mummery et al., 2003), acted as a functional syncytium with cell-to-cell coupling 
between the hESC-CMs as was evident from the homogeneity of the AP frequency 
within beating areas and from connexin stainings. These findings were the same 
with both differentiation methods used (spontaneous differentiation in EBs and 
END-2 co-culture). The AP firing was usually constant, but in a few cells different 
firing patterns were observed confirming earlier findings (He et al., 2003b) which 
may be due to intermittent conduction block caused by structural discontinuities 
within the cellular network (Kehat et al., 2002).  
According to the immunocytochemisty and action potential studies, most of the 
differentiated cardiomyocytes were ventricular type cells. A slight variation in 
subtype content was seen between different cell lines as has been reported by others 
(Moore et al., 2008) and a difference between the differentiation methods was also 
observed (80% and 100% of END-2 and EB-derived cardiomyocytes, respectively). 
The differentiation methods had affected AP properties. However, both of the 
methods resulted in cardiomyocytes with a great heterogeneity in their electrical 
properties with as many as about one third of them presenting a fairly mature 
phenotype. Unlike an earlier report (Sartiani et al., 2007) the AP-phenotype and 
maturity of the hESC-CM did not correlate with the age of the hESC-CM.  
The ventricular phenotype and its heterogeneous properties are concur with 
earlier reports  (He et al., 2003b, Mummery et al., 2003, Cao et al., 2008). The 
ventricular-like AP properties of hESC-CM previously reported have been mostly 
comparable to those of cultured human fetal myocytes, with MDPs of ~-50 mV and 
upstroke velocities of <30 V/s (Mummery et al., 2003, Sartiani et al., 2007, Cao et 
al., 2008), even though more mature cardiac phenotypes in hESC-CMs have also 
been reported (Satin et al., 2004). However, in present study as many as one third of 
hESC-CM exhibited a more mature phenotype with MDPs of < -70 mV and 
upstroke velocities >140 V/s. The demonstration of the presence of cardiomyocytes 
with dV/dtmax of over 150 and MDP of close to -80 is very important and suggests 
that mature human cardiac cells can be produced from hESCs, but the optimal 
conditions are still to be defined. 
Corroborating earlier studies (Kehat et al., 2001, Xu et al., 2002, Mummery et al., 
2003, Norstrom et al., 2006), the electrical activity and chronotropic response 
characterization revealed that the functional adrenergic mechanisms as well as L-
type Ca2+ channels were present in cardiomyocytes derived from hESCs. In 
addition, according to the results of studies made with hERG blocker E-4031 and 
veratridine, hESC-CM could provide a sensitive cellular model to detect signals for 
proarrhythmic toxicity and antiarrhythmic efficacy.  
Differentiated hESC-CM express endogenously the repertoire of cardiac ion 
channels, unlike the heterologous expression in transfected cells currently used in 
long QT assays by the pharmaceutical industry (Redfern et al., 2003, Pollard et al., 
2008). The effects of new chemical compounds could therefore be investigated with 
those cells having native cardiac electrophysiological phenotype. However, the 
heterogeneous nature of differentiated hESC-CMs is an important limitation at the 
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moment. Therfore more defined and targeted differentiating methods are needed for 
obtaining more homogenous cardiomyocyte populations.  
6.5 Future perspectives 
The ultimate goal for stem cell research is to cure patients with diseases caused 
by the loss of functional tissue such as in chronic heart disease. However, it has 
become clear that pluripotent stem cell derived cardiomyocytes are not ready for the 
clinical use in the near future because a lot of development and basic research is still 
needed. Recent developments in the derivation of induced pluripotent cells in 
addition to more defined culture and differentiation methods, has turned the focus of 
research towards pluripotent stem cell derived cardiomyocytes to be used as a 
disease model and in the pre-clinical drug discovery and safety pharmacology 
applications.      
Even though this goal is easier to achieve, much work is still needed. The cardiac 
differentiation is still inefficient and uncontrolled. Therefore effective methods for 
differentiation that supply homogenous populations of cardiomyocytes of sufficient 
quality, reproducibility and in large quantities are prerequisite for applications in the 
pharmaceutical industry as well as for clinical use.  
The differentiated cardiomyocytes are a mixed population consisting of non-
cardiac cells and cardiomyocytes with several subtypes and maturation stages. For 
studies of the pathogenesis disease or for testing new potential drug molecules the 
cardiomyocyte population should be of one subtype (e.g. ventricular) and of the 
mature, adult-like phenotype. In addition, for standardized testing and reliable 
research of the pathology of diseases, this is necessary because many diseases do 
not manifest the fetal staged cardiomyocytes. 
Moreover, other non-cardiac cell types are present in the differentiated cell 
populations. This is not only a disadvantage because the target is a cardiac tissue 
model, other cell types such as fibroblasts and endothelial cells are needed. 
However, the population should again be standardized and composed of desired 
cells with right proportions. It is likely that cells cannot form three-dimensional 
tissue model structure by themselves and some biomaterial is needed to give cells 
support, attachment surfaces and nutrition.      
The invention of induced pluripotent cells was a revolutionary step in stem cell 
research. However, iPS cell technology is in its infancy and needs a lot of 
development, for example in the induction step as well as in culture conditions. 
Defined culture conditions are still also under development for hESC. Due to the 
similarities of these cells, the development of defined culture conditions is 
beneficial for both pluripotent cell types.   
Even though the pluripotent stem cell derived-cardiomyocytes are not suitable for 
clinical use in the foreseeable future and many obstacles have also to be overcome 
before they can be used in drug discovery, they offer tremendous opportunities for 
basic research, the pharmaceutical industry and for regenerative medicine.  
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7. Conclusions  
The aim of this work was to evaluate the differentiation of hESC and iPS cells to 
cardiomyocytes and to thoroughly characterize the differentiated cells. Based on the 
four studies presented the following conclusions can be drawn:    
 
• Significant differences between the cardiac differentiation potentials of 
different hESC lines were found even though the cell lines were derived and 
maintained in a similar fashion. This suggests that the embryo or the part of 
inner cell mass that contributes to the cell line could already be committed to 
certain lineages.  
• Culture conditions have an effect on the cardiac differentiation capability of 
pluripotent stem cells. hESC maintained on MEF feeder cells had better 
cardiac differentiation potential than cells maintained on hFF cells. 
Furthermore, MEF feeder cells support the undifferentiated state of cells 
originally derived and maintained on MEF better than hFF feeder cells. 
• The EB formation as well as the temporal and spatial organization of germ 
layers took place in a fairly similar manner during early EB differentiation. 
All germ layer markers were present in all lines, but the EB structure was not 
very organized and no obvious distinct trajectories were formed. The cardiac 
differentiation potential of hESC lines could not be predicted by the number 
or localization of early germ layer marker proteins or by the morphology of 
EBs in the early stages of differentiation. 
• Despite the wide variation in the cardiac potential of hESC lines, 
cardiomyocytes produced from these lines with two different differentiation 
methods express proper cardiac markers and have properly functioning L-
type Ca2+ channels and a β-adrenoreceptor system indicating that these cells 
could be used as a cell model for human cardiomyocytes in pharmacological, 
toxicological and cell therapy trials in the future. 
• hESC-CMs exhibited electrophysiological heterogeneity, but fairly mature 
adult cardiac phenotype could also be detected. The study using two 
differentiation methods produced similar cardiac cell heterogeneity. The 
demonstration of cells with fairly mature electrical phenotype, however, 
suggests that with more specific and detailed differentiation methods, mature 
and more homogenous cardiomyocyte cultures could be obtained.  
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